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FOREWORD 
Genetic testing is used to identify alterations in the DNA sequence that correlate with a 
disease or higher risk to develop a disease. This type of tests can be used for diagnosis 
before any symptoms of disease are recognisable and to determine the personal risk for 
certain multifactorial diseases. Thus, the results of genetic testing can have far reaching 
effects on an individual's life. 
The European Commission's Joint Research Centre (JRC), in particular its Institute for 
Prospective Technological Studies (IPTS), has been active in the field of genetic testing 
services since 1999. Within the IPTS' Futures project (1999) quality standards of 
genetic testing services was one of the topics discussed. In July 2000, IPTS organised a 
workshop, including all major stakeholders, where the need to better ensure the quality 
of genetic testing services at EU level was stressed. 
The JRC received, in October 2001, a request from DG RTD to carry out a prospective 
study on the technical needs and options for the quality assurance and harmonisation of 
genetic testing services in Europe. In response to this request, IPTS and IRMM (Institute 
for Reference Materials and Measurements) began work on a project that aims to the 
identification and assessment of the means to guarantee that genetic testing services 
provide the same high quality within the enlarged EU. 
In March 2002, a workshop with international experts was organised by IPTS to discuss 
the current situation and to identify lines of work towards achieving those goals. This 
workshop has been the starting point of a recently launched study, to be done in 
collaboration with the ESTO Network, to assess different harmonisation scenarios. 
During this workshop, experts and JRC agreed on the need to obtain updated "field" data 
on the situation of genetic testing services in each of the Member States. It was deemed 
essential, in order to start the study, to obtain and present background information for 
each Member State on 
• the number of tests and conditions tested per year, 
• the main centres providing the services and their regional distribution, 
• ownership (public vs. private) and type of centre activity (health care, research or 
teaching), 
• the framework for accreditation of services and personnel, 
• the referral system in place, specially for rare diseases, 
• data handling policies (informed consent and privacy issues), 
and other data that would provide an accurate picture of the current situation on which to 
build our research. This has been attempted several times and reports exist, but the 
information is fragmented and/or out of date. 
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This is why, in order to provide an example of the type of information that would be 
required, IPTS asked the Andalusian Agency for Health Technology Assessment 
(AETSA) to provide a pilot report on the situation of genetic services in one Member 
State (Spain). This report will be given to the consortium formed in the ESTO to 
illustrate what ideally would be needed for the whole, enlarged EU. 
The pilot survey on the current situation and practices of genetic services for hereditary 
diseases in Spain was commissioned to AETSA because of their ample experience in 
this type of studies. They had carried similar surveys at national level in other health 
technologies and they had full support from the Spanish Society for Human Genetics, 
which was essential in this case. 
The survey was revealing as to the constantly increasing use of genetic testing in the 
EU, the current needs, and timely emergence of the JRC activity in the field. 
Emilio Rodríguez-Cerezo 
Life Sciences Co-ordinator, IPTS 
Seville, October 2002 
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EXECUTIVE SUMMARY 
This report presents the results of a survey on the current situation and practices of 
genetic testing services for hereditary diseases in Spain, including tests available, 
characteristics of centres, patient referral pathways and accreditation processes. 
The study targeted molecular DNA testing for diagnosis of hereditary diseases, 
excluding other types of diagnostic tests, such as cytogenetics, biochemical testing, or 
pharmacogenetics. The survey was carried out at the beginning of 2002. 
A total of 53 centres performing genetic testing for hereditary diseases in Spain were 
identified, of which 42 are public and 11 private. The majority of laboratories belong to 
a hospital, and there is at least one centre performing genetic testing in each of the 17 
autonomous regions of Spain. However, some regions as Catalonia, Madrid, Aragon, 
Basque Country or Galicia have higher numbers of centres per capita than the rest. 
Due to the decentralised organisation of the Spanish health systems, a majority of 
centres are receiving patients from other regions or even countries, for at least one given 
hereditary disease, without any formal organisation. An official accreditation system is 
not in place, but the Spanish Society for Human Genetics provides an accreditation 
system for professionals. Some Spanish centres are participating in quality control 
schemes developed by the European Molecular Genetics Quality Network (EMQN) or 
the Cystic Fibrosis European Network. At least two centres are in the process of getting 
the ISO 9000 - 9002 accreditation. 
According to survey results, 214 genetic conditions are currently being tested in Spain. 
The conditions most frequently tested are those with a higher frequency in general 
population (hemochromatosis, coagulation disorders, fragile X, cystic fibrosis or 
haematologic cancers) and they are performed in several centres and regions. 
In Spain, there are no specific regulations or guidelines on molecular genetic testing, 
neither at state nor at regional level. Specific committees on genetic testing do not exist. 
Referral of patients for genetic testing is nearly exclusive of hospitals and specialised 
care, without any established standard protocol. It can be performed for clinical reasons 
or as a part of a research protocol. According to the survey, informed consent is 
requested by 90% of centres but there is no harmonised procedure. Usually, the 
physician requesting the test gets informed consent from the patient, although there 
could be important gaps in this process. 
More than 95% ofthe tests are financed by public institutions (hospitals or universities) 
from their global budgets, without specific earmarked money. Usually centres and labs 
perform genetic testing only for a small number of conditions, and in many cases the 
test protocols used are home-brew. Payment for the tests performed in other centres, 
either in Spain or abroad, could be in some cases cumbersome due to the lack of 
established mechanisms, particularly for rare diseases. 
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Overall, the results from this pilot study show that the system lacks clear organisation 
and there is no formalised quality assurance scheme in place, although some centres 
participate in European schemes. "Non-official" reference centres for rare diseases 
appear and disappear depending on research trends. At the same time, the response to 
the survey from all centres was very positive and most of them acknowledged the need 
and willingness to join a European level quality assurance harmonisation effort. There 
is also an increasing trend in the number of types of hereditary diseases for which tests 
are being offered, which is a direct consequence of continuous research closely 
connected to practice. 
The survey presented a picture of the situation of Spain that seems to be concordant 
with the situation in many Member States. 
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1. Introduction 
Many hereditary diseases are known to be caused by a change in the DNA code of a 
single gene, also called monogenic diseases. The number of monogenic diseases 
described is continuously increasing and in the year 2000, the data bank of Online 
Mendelian Inheritance in Men (OMIM)1 included about 1500 clinical disorders for 
which mutations were listed. This number increases as more is known about the human 
genome. Currently, the laboratories included in the European Directory of DNA 
Diagnostic Laboratories (EDDNAL)2 perform genetic diagnostic tests for 580 genetic 
conditions. 
Apart from monogenic diseases, there are other diseases in which hereditary factors 
play a role, but which are determined multifactorially, i.e. their development usually 
involves several genes and also environmental factors. Among these disorders are 
hereditary types of cancer, susceptibility to thrombosis, asthma, hypertension, diabetes, 
Alzheimer disease, atherosclerosis or others. These multifactorial diseases not only 
concern rare mutations, but also combinations of frequently occurring variations 
(polymorphisms). The relationship between a mutation and the onset of the disease is 
often less clear in these cases. The likelihood of a disease occurring as a result of a 
mutation varies considerably. In the case of factor V Leiden mutation in heterozygotes, 
for example, the likelihood of venous thrombosis is four to nine times greater, with a 
risk of 0.1 percent per year of developing symptoms. On the other hand, some genetic 
risk factors are very powerful, as in the case of BRCA mutations with a 60-85 percent 
risk of developing breast or ovarian cancer in carriers 
An important number of the hereditary conditions that can be detected by means of 
genetic testing are "rare diseases", that is those diseases with a prevalence of less than 5 
per 10,000 in the population. With Decision No 1295/1999/EC, the European 
Parliament and the Council of the European Union of 29 April 1999 adopted a 
programme of Community action on rare diseases within the framework for action in 
public health (1999 to 2003). 
In spite of their low prevalence, these diseases are responsible for conditions that imply 
an important detriment for those who suffer them and their families. Also these diseases 
have an important effect on the demand for health and social services. At the same time, 
provision and quality assurance of genetic testing for rare hereditary diseases pose 
distinct problems. Given that research into genetic mutation is often complex, while 
laboratories performing genetic testing of the most common diseases exist in most 
European countries, only a few laboratories are in the position to supply an appropriate 
test for certain rare diseases. 
Genetic testing differs from other medical testing in that it can be predictive for future 
onsets of (severe) disorders and that it can also be relevant for the patient's relatives. 
The information obtained from genetic tests is invariable, as it refers to a DNA 
sequence, therefore tests are carried out only once. Thus, the results of genetic testing 
' http://www.ncbi.nliTi.nih.gov/OMIM/ 
2 http://www.eddnal.com/ 
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can have far reaching effects on an individual's life, which renders quality assurance of 
genetic testing services an issue of utmost importance. 
The estimated incidence or prevalence of some hereditary diseases for which tests are 
available is presented in Table 1. For instance hemochromatosis, the most frequent 
hereditary genetic disease, affects about one in two hundred people, but it has been 
estimated that one in eight people of Northern European descent are carriers of the 
disease. Population screening for these conditions could have important consequences 
and proposals in that direction should be rigorously evaluated. 
Table 1. Estimated incidence or prevalence of some hereditary diseases 
Disease Estimated incidence or prevalence (Source) 
Becker muscular dystrophy 
Cystic fibrosis 
Birth incidence: 1 in 18,500 live born males (EMQN) 
Incidence: 1 in 2,500 live births (Gelehrter 1998) 
Duchenne muscular dystrophy 
Familial breast cancer 
Birth incidence: 1 in 4,000 live born males (EMQN) 
Incidence: 4 to 8 in 1,000 women (EMQN) 
Familial adenomatous polyposis coli Prevalence: 1 in 8,000 to 1 in 13,500 live births (EMQN) 
Fragile-X syndrome Prevalence: 1 in 5000 males (EMQN). 1 in 1039 males (Pembrey 2001) 
Friedreich ataxia Prevalence: 1 to 2 in 100,000 (EMQN) 
Haemophilia A Prevalence: 1 in 5,000 males (EMQN) 
Haemophilia Β Prevalence: 1 in 25,000 males (EMQN) 
Hemochromatosis Prevalence: 5 in 1,000 people (Bulaj 2000) 
Hereditary motor and sensory 
neuropathies 
Prevalence: 10 to 40 in 10,000 (EMQN) 
Hereditary non-polyposis coli 0.5% to 13% of all the colorectal cancer at the population level(Percesepe 2001 ) 
Huntington disease Incidence: 0.65 per 100,000 per year (McCusker 2000); 
Prevalence: 5.38 in 100,000 (Burguera 1997) 
Mitochondrial disorders 
Incidence of mitochondrial encephalomyopathies in 
children <6 years of age 1 in 11,000. Leigh's syndrome 1 
in f 32,000, and both Alper's syndrome and infantile 
mitochondrial myopathy with cytochrome C oxidase 
deficiency 1 in 51,000. The point prevalence (as of 
January 1, 1999) of mitochondrial encephalo-myopathies 
in children under 16 years of age is 1 in 21,000. (Darin 
2001) 
Myotonic dystrophy Incidence: 1 in 8,000 (EMQN) 
Prader Willi / Angelman syndromes Incidence: 1 in 15,000 to 1 in 20,000 (EMQN) 
Spinal muscular atrophy Birth incidence: 1 in 10,000 (EMQN) 
Spinocerebellar ataxias (other than 
Friedreich ataxia) 
Prevalence: 1 in 100,000 (EMQN) 
Y-chromosome microdeletions Prevalence: 7 in 100 infertile men (EMQN) 
ΈΜΟΝ: http://www.emqn.org/bpguidelines.htm (accessed 2002-03-23) 
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1.1 Technical issues 
Genetic testing is a field with technical particularities because it changes following the 
rapid developments around the recently opened genomics era. The vast amount of 
information generated every year by genomics is translated into new genetic tests for 
diseases. These tests have little time to move from the research status to the quality 
status required for a routine clinical analysis. Also, since the technology and the 
knowledge are so new, very often the research labs are doing the tests (because the 
typical clinical labs are not used or do not master the techniques). Research labs are not 
accustomed to the quality control needed in routine clinical laboratories 
Genetic testing implies accurate observation of one or more areas of a gene to check 
whether a specific alteration can be observed. Some diseases are linked to one alteration 
located in a well known specific area of one gene, a hot spot, a situation which 
simplifies the diagnosis of the genetic alteration. That is the case for some diseases like 
fragile-X disease, Steiner disease or some ataxias. In frequent genetic diseases such as 
hemochromatosis or cystic fibrosis there are two or three hot spots in which the 
predominant mutations can be easily diagnosed. In other cases, like breast cancer 
mutations, there are no hot spots, and the diagnosis of the alteration could imply the 
analysis of many areas of a gene until one alteration is found. 
Moreover, the genetic alterations responsible for a specific genetic disease can vary 
within populations from one geographic area to another. One mutation can be 
responsible for almost all cases of a disease in one area or ethnic group but this may not 
be the case in another area. That implies that the techniques for the diagnosis of a 
particular genetic alteration could vary from one geographic area to another, according 
to the different mutations. 
It is also important to consider that there could be different techniques to reliably and 
accurately diagnose a specific genetic alteration. The selection ofthe technique depends 
in many cases on the personal preference of the professional or on reasons such as 
resources available. The efficiency and costs of the resources involved are elements that 
have to be taken into account when deciding which diagnostic technique is more 
adequate for a given lab. 
Labs use specific reagents for the PCR (polymerase chain reaction) and other such 
techniques. These reagents can be provided by a commercial company or developed by 
the same centre performing the test, the so-called home-brew tests. These home-brew 
tests (with in-house prepared materials) fall outside any regulatory frame unlike 
commercial in-vitro diagnostic products regulated by the IVD (in vitro diagnostics) 
European directive. 
In Table 2, different techniques for molecular genetic diagnosis of some hereditary 
diseases are summarised. A much more detailed information for each disease can be 
found in the guidelines included in the web page of the European Molecular Genetics 
Quality Network (http://www.emqn.org/guidelines.htm). 
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Duchenne muscular dystrophy 
Multiplex PCR 
Microsatellite analysis 
Mutation analysis (MAPH, DHPLC, DGGE, protein 
truncation test [PTT], myoD-induced myogenesis) 
Familial Breast cancer PCR analysis Mutation analysis 
Familial adenomatous polyposis 
coli 
Linked-marker testing 
Mutation analysis (SSCP, DGGE, heteroduplex analysis, 
RNAse protection and chemical mismatch cleavage) 
Fragile-X syndrome 
PCR analysis 
Southern blot analysis 









Southern blot analysis 
Mutation analysis 
Factor Vili gene inversion 






Factor IX deletions 
Direct sequencing 
Hereditary motor and sensory 
neuropathies 
PCR methods based on STR markers 
RFLP Southern blot methods 
Linked-marker testing 
Hereditary non-polyposis coli 
RT-PCR 




Huntington disease PCR analysis Southern analysis 
Myotonic dystrophy PCR analysis Southern analysis 









Spinocerebellar ataxias (other 
than Friedreich ataxia) 
PCR analysis 
Southern analysis 
Y-chromosome microdeletions PCR multiplex (at least duplex) 
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2. Survey on genetic testing in Spain 
In the context of a prospective study analysing the technical needs and options for 
harmonisation and quality assurance of genetic testing services in the EU, a pilot survey 
was performed, at the beginning of 2002, on the current situation and practices of 
genetic testing services for hereditary diseases in Spain. The survey aimed to assess the 
situation in Spain, as a case example for EU general situation. The methodology and 
results ofthe survey are presented below. 
Some related topics not covered in the survey of centres have been explored by means 
of literature review and expert consultation and are covered in Chapters 3 and 4. These 
topics include the existence of specific regulations or guidelines on genetic testing in 
Spain, the referral pathways for patients and the question of who is responsible to 
provide relevant information to patients. 
2.1 Objectives 
• To identify centres performing genetic testing for hereditary diseases in Spain. 
• To list hereditary diseases for which genetic testing is performed in Spain and the 
number of tests performed for each disease during the year 2001. 
• 
• 
To describe some laboratory characteristics: ownership and type of centre activity 
(health care, research or teaching). 
To detect centres of reference at the regional or state level, particularly for rare 
diseases. 
To explore processes of accreditation and quality assurance in those centres. 
To describe centre policies to ensure informed consent and privacy ofthe results. 
2.2 Methodology 
The following steps have been carried out: 
1.- Internet search for resources on this field and Spanish associations web sites. 
2.- Exploratory initial personal interviews on-site with key stakeholders, representatives 
of professional organisations or national experts in the area. Also telephone interviews 
with other key stakeholders of groups or organisations. The organisations involved in 
the area that were contacted are listed in Annex 1. 
3.- Identification of different centres or units that perform genetic testing for hereditary 
diseases in Spain. To achieve this we have combined different strategies: 
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• Internet search in relevant on-line directories and web pages (EDDNAL 
European Directory of DNA Diagnostic Laboratories, Spanish Society of Human 
Genetics and Spanish Society for Neurology). 
• General internet search using the terms "diagnòstico genético" (genetic testing). 
• A request to the experts identified to check the list of centres and complete it. 
• Telephone interviews with professionals performing genetic testing in all the 
centres identified in the previous steps, asking for other units in their centres that 
perform genetic testing. All persons contacted who were performing genetic testing 
for hereditary diseases agreed to provide their e-mail address and to fill in the 
questionnaire. 
• A provisional list of centres previously identified was sent to all those receiving 
the questionnaire, and they were also asked to check for any missing centres or 
units, with special reference to their autonomous community. 
4.- Questionnaire 
A questionnaire was designed to cover all the areas included in the objectives of the 
study. 
In order to improve the response rate, and due to the exploratory approach of the study, 
we decided to make a questionnaire that could be answered in ten to fifteen minutes. 
The questionnaire included closed questions (yes/no type) and open-ended ones to give 
the opportunity to participants to express freely what they believed to be relevant. 
To facilitate respondents to answer the questionnaire, different lists of conditions that 
could be tested by means of genetic tests were provided. Those lists were the ones used 
by the Spanish Society of Human Genetics (Asociación Española de Genética Humana) 
in the directory of centres and genetic tests included in the web page of that 
organisation. 
An initial version was drafted and sent to some key stakeholders. A validation of the 
questionnaire or a pilot study has not been carried out, due to the time constraints of this 
study. The questionnaire is attached in Annex 2. 
5.- Questionnaire was presented by telephonic contact and sent by e-mail 
As explained above, professionals of the different centres or units identified in previous 
steps were contacted and the origin and objectives ofthe study were explained to them 
by phone. 
The questionnaire was sent with a introductory letter (Annex 3) by e-mail explaining the 
objectives and institutions involved in this study to all the 53 centres identified. In many 
of them, there were several units involved in genetic testing and the questionnaire was 
sent to all of them, and to some other professionals identified in the previous steps. 
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The President ofthe Spanish Association for Human Genetics, Dr Isabel Tejada, and the 
Coordinator ofthe Human Genetic Section ofthe Spanish Society of Genetics, Dr Joan 
Fibla, have addressed all members of both professional associations, expressing the 
associations' support to this study. They also have sent them a copy of the 
questionnaire. 
An e-mail with the questionnaire was also sent to all the members of the Working 
Group on Molecular Genetics in Paediatric Endocrinology, of the Spanish Society of 
Paediatric Endocrinology. 
To improve the survey response rate, a reminder was sent three weeks after the 
questionnaire. Centres were contacted again, usually by telephone or by the e-mail in 
the cases in which telephonic contact with the responsible person was not possible. 
2.3 Results ofthe survey 
2.3.1 Characteristics and geographic distribution of the centers identified 
53 centres performing genetic testing for hereditary diseases have been identified. The 
term "centre", as used in this context, means institutions (i.e. hospitals or universities) 
as a whole. Those hospitals or universities with more than one unit performing genetic 
testing have been considered as a single centre for the purpose of this study. 
The list of centres identified, units involved and contact persons, their postal and e-mail 
addresses and the telephone number, can be found in Annex 4. 
All 53 centres (100 %) answered the questionnaire. Taking into account the voluntary 
participation of the centres, this response rate probably reflects both the collaborative 
attitude of those involved in genetic testing and the need for an updated directory of 
centres doing those tests, as it has been expressed by many professionals contacted. 
Table 3 and Figure 1 show the distribution by type of centre. 
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Figure 1. Types of centres performing genetic tests in Spain, by percentages 
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The number of centres identified in each autonomous regions is shown in Table 4, 
including population size and the number of conditions tested in each region. There is at 
least one centre performing genetic testing in each autonomous region in Spain. 














































































Source; I.N.E. Total includes two autonomous cities Ceuta (75,694) and Melilla (68,789) 
The Spanish health system has a high level of decentralisation. There are 17 
Autonomous Regions with Regional Health Services, fully responsible for services 
provision and financing. As it can be seen in Table 4, the geographical distribution of 
the number of centres doing genetic testing does not directly correlate with the 
population size ofthe regions. 
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Figure 2. Distribution of centres and genetic conditions (in brackets) tested by 
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Catalonia and Madrid have a large proportion of centres, with nine centres in each 
region. Their population is smaller than that of Andalusia, where only 5 centres are 
doing genetic tests. In part, this can be explained by the presence of some private 
centres in Catalonia and some national research centres located in Madrid. 
In regions such as Aragon, with a population of 1,199,753 persons, 3 centres are doing 
genetic tests for 53 conditions. In Galicia, with a population of 2,732,926 persons, 4 
centres are doing tests for 68 conditions. Basque Country is also a region with small 
population and in comparison a high number of type of tests offered. 
These imbalances in the distribution of centres and conditions tested probably reflects 
the unplanned development of genetic testing in Spain and the existence of some units 
very active in research in some autonomous regions. 
The consequences of this uneven distribution of centres and conditions tested between 
regions on possible differences in the accessibility to genetic testing have not been 
analysed. This topic would deserve more in-depth research. 
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2.3.2 Genetic conditions tested 
According to the data obatained in the questionnaires, 214 genetic conditions are 
currently being tested in Spain while EDDNAL, the European directory contains 580 
genetic conditions tested in European centres. 
Detailed results for all the conditions are shown in Annex 5, classified by functional 
areas (neurological diseases, haematological diseases, metabolic problems, hereditary 
cancers, collagen diseases, primary immune-deficiencies, mitochondrial diseases and 
others). 
In Annex 6, results are presented grouped by autonomous regions. The number of tests 
performed for each disease, in each centre, in the year 2001 is shown where available. 
For some centres the precise number of tests for a specific condition is missing, 
although it is known that the test is available at the centre. 
Figures of tests for each condition include those performed for research purposes and 
those for genetic counselling in the context of clinical practice. These data are estimated 
from survey responses, and therefore should be interpreted with caution. 
It is also possible that data from some specific units within centres are missing. It could 
be due to either lack of information about specific subunits in the identification phase or 
non-response to the questionnaire. 
In Table 5, summary data on the 15 conditions most frequently tested in 2001 are 
presented. They correlate with those with a higher frequency in the population 
(hemochromatosis, coagulation disorders, fragile X, cystic fibrosis or haematologic 
cancers), also having a higher interest and validity for clinical purposes. Also, it is not 
surprising that testing for those frequent conditions is done in numerous centres and 
regions. The mutations responsible for the diseases are well known and the techniques 
are reliable and relatively easy to learn. 
Research trends, however, also influence which conditions are being tested more often, 
as a reflection of the close relationship between research and clinical application in the 
field. Centres investigating a particular disease will carry a higher number of tests for 
it, reflecting a higher sample size for a particular test even though the alteration is not 
more common nor more often requested by physicians. Hence, genetic testing for 
Alzheimer disease, for example, was one of the most frequently performed tests in the 
year 2001, though it currently has little clinical usefulness. According to experts, it is an 
area of very active research and many tests are performed. 
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Table 5. Conditions most frequently testée 
Hemochromatosis 
Thrombophilia (Mut. G1691A of Leiden's 
gene) (Mut G20210A of prothrombin gene) 
Prothrombin gene 
Factor V Deficiency 
Fragile X Syndrome 
Cystic fibrosis 
Leukemia and lymphoma 
Homocystinuria 
Myotonic dystrophy Steinert 
Apolipoprotein Β (APOB) deficiency 
Ρ 53 exons 4,5,6,7,8 
21-hydroxylase deficiency 
Alzheimer (Presenilin 1, APP, APOE) 
Azoospermia and oligospermia 
ι factor V 
Dominant Ataxias (ADCAS) SCA1; SCA2 (Machado), 
SCA3; SCA6; SCA7; SCA8; SCA9; SCA10; SCA12 



















































2.3.3 Reference centres 
A question was included in the survey about reference centres at regional or national 
level (data presented in Table 6). Due to the exploratory nature ofthe survey and for the 
sake of brevity, questions on specific diseases for referral were not included in the 
questionnaire. 
At least 36 centres considered themselves as reference centres at the regional or national 
level. This probably shows that when a centre starts doing testing for one disease it 
usually ends up being the only one doing it at the regional level and in the case of less 
frequent conditions becomes reference centre at a national level. 
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Table 6. List of centres of reference 
Centre 
Hospital Virqen del Rocío Sevilla 
H. San Cecilio Granada 
Hospital Carlos Haya Málaga 
Hospital Miguel Servet Zaragoza 
Universidad de Zaragoza 
Centro de Analisis Genéticos Zaragoza 
Hospital Central de Asturias 
Hospital Son Dureta. Mallorca 
Hospital Valdecilla Santander 
Universidad de La Laguna Tenerife 
Hospital Materno Infantil de Badajoz 
Centro de Patología Celular Barcelona 
Hospital Clínico de Barcelona 
Hospital San Juan de Dios Barcelona 
Centro Genética Médica y Molecular-IRO 
Hospital del Mar - Facultad de Ciencias de 
la Salud (Universität Pompeu Fabra) 
Hospital Pare Taulí 
Hospital Valle Hebron 
Hospital San Pablo Barcelona 
Centro Oncológico de Galicia 
Hospital de Conxo 
Hospital Juan Canalejo La Coruna 
Hospital Clinico de Santiago 








Regional and national 
Not stated 
Not stated 
Regional and national 
Not stated 
Not stated 
Regional and national 
National 
Regional and national 
National 
Regional and national 
Regional and national 
Regional and national 
Regional 
Regional 






Acute promielocitic leukaemia, 












Rett, CMT1A, HNPP 
Not stated 
Leukaemia and Lymphoma 
(Hosp del Mar) Williams 
Syndrome (UPF). 
Not stated 
Male pseudo hermaphroditism 







Hospital La Paz Madrid Regional, national 
international 
and Cystis fibrosis, miotonic 
dystrophy, alfalantitripsina 
genotyping, Duchenne muscle 
dystrophy, Huntington disease, 
hemochromatosis, 21-
hidroxilasa deficiency, 
achondroplasia, GH receptor 
deficiency, acute intermittent 
porphyry, erithropoietic 
congenital porphyry, MODY type 
diabetes. 
H. Ramón y Cajal Madrid 
Centro de Diagnóstico de Enfermedades 
Moleculares - U. A. de Madrid 







Hospital Gregorio Marañón Madrid Regional and national 21-hidroxilasa deficiency, 11-
hidroxilasa deficiency, Turner 
syndrome, discondrosteosis, 
achondroplasia, small height 
with skeleton disproportion, 
hypochondroplasia 
Hospital 12 Octubre Madrid 
Centro de Investigación sobre Anomalías 
Congénitas Madrid 
Centro Nacional Investigaciones 
Oncológicas (CNIO) Madrid 
Clinica Universitaria Pamplona 
Hospital de Basurto 
Hospital de Cruces Baracaldo 
Hospital Donostia 





Regional and national 
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2.3.4 Accreditation related topics 
Accreditation systems could target the professionals and/or the centres performing the 
tests. Regarding professionals, there is no biomedical specialty or university degree on 
human genetics in Spain. This is one of the problems mentioned by many in the 
interviews and questionnaires. 
The Spanish Society for Human Genetics has a procedure to accredit individual 
professionals (http://www.uam.es/otros/AEGH/paginas/acreditacion.htmn. These 
professionals must be members of the association, for at least two years, and either a 
medical doctor, a biologist, a pharmacist, a chemist or a biochemist. They must develop 
their professional activity in the area of human genetics. A group of experts appointed 
by the society analyses the curriculum of the applicants and by means of an explicit list 
of areas considered, scores the different merits of the applicant, providing the 
accreditation if he/she reaches a certain level. This process is voluntary and has no legal 
backing or support from official institutions. To date, about 180 professionals have 
passed the procedure. 
Regarding the centres or diagnostic laboratories, in Spain there is no specific system for 
the accreditation or control of the centres which perform any kind of genetic test. In 
some autonomous regions, laboratories dealing with clinical analysis are subject to an 
accreditation process for biological testing, but it is not an iterative process with 
periodic re-evaluation. 17 Spanish centres out of the total sample surveyed are 
voluntarily included in the EDDNAL directory and almost all of them are active 
participants. 
2.3.5 Quality assurance related topics 
Some of the centres are carrying out quality assurance activities for specific tests or 
diseases. Of those centres registered in EDDNAL, some are participating in quality 
control schemes developed by the EMQN or the Cystic Fibrosis European Thematic 
Network. Those who stated so in the questionnaire are listed in Table 7. 
At least two centres are in the process of getting the ISO 9000 - 9002 qualifications 
(Hospital Materno Infantil Las Palmas, Hospital Clínico Barcelona). 
2.3.6 Informed Consent and Privacy of Data 
According to survey replies, informed consent of the patient is requested by 90% of 
centres. Usually, the physician requesting the test is the one who normally obtains it 
from the patient. In tests performed in the context of research studies the researchers are 
responsible for the informed consent process. 
According to the survey, almost all centres have developed specific policies to warrant 
the privacy ofthe tests results. 
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Centro Genética Médica y Molecular 
Hospital San Pablo Barcelona 
-IRO 
Cystic Fibrosis Centro de Análisis Genéticos Zaragoza 
Centro de Bioquímica y Genética Clínica de 
Murcia 
Centro de Patología Celular Barcelona 
Hospital La Fé Valencia 
Hospital La Paz Madrid 
Hospital Materno-lnfantil Las Palmas 
Hospital San Juan de Dios Barcelona 
Hospital San Pablo Barcelona 
Hospital Son Dureta Mallorca 
Institut Resercha Oncológica 
Instituto Biología Genética Molecular. 
Valladolid 
Oncológico de Galicia 
Duchenne/Becker Hospital San Pablo Barcelona 
Fragüe X syndrome Centro de Bioquímica y Genética Clínica de 
Murcia 
Huntington Hospital de Conxo Santiago 
Prader Willi - Angleman Centro de Bioquímica y Genética Clínica de Murcia 
2.3.7 Financing of the tests and related topics 
According to survey replies, more than 95% of the test are financed by public 
institutions, whether hospitals or universities. 
Experts mentioned that there is no earmarked money for these tests, except when tests 
are performed in the context of specific research studies, and in these cases the 
financing ofthe tests is usually limited to the duration ofthe study. 
The average cost of performing one test is in most cases very dependent on the number 
of tests performed in one centre for a specific disease. Average costs of genetic tests 
could be around €240, ranging from €120 for cystic fibrosis to €330 for a study for 
ataxia, according to the estimate of one expert. 
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3. Genetic testing products on the market 
In order to get information on commercial tests available in Spain, different sources 
were contacted and surveyed : 
• Ministry of Health, Department of Pharmacy and Health Products. No list of 
products is currently available, but there is a Royal Decree on health products for in 
vitro testing (R.D.I662/2000) due to enter into force before the end of 2003. This is 
further explained in section 4.2. This Decree will make compulsory for all new 
products to be sold in Spain to have CE mark and to be registered, but no further 
information was available when carrying the survey. 
• 
• 
FENIN, the Spanish Federation of Health Technology Industries (Federación 
Española de Empresas de Tecnología Sanitaria: http://www.fenin.org) is represented 
in the European Diagnostic Manufacturers Association, EDMA (http://www.edma-
ivd.be/), Executive Committee. It comprises 40 companies involved in In Vitro 
Testing, but there is neither a specific directory of companies marketing products, 
nor a list or database with commercial products for genetic testing of hereditary 
diseases in Spain. 
Consultation with professionals involved in the field. Information on most frequent 
products and companies was provided and these were contacted. 
From these sources, it was only possible to get incomplete information. Most of the 
centres and labs performing genetic testing only test for a small number of conditions, 
and in many cases tests are home-brew. Various commercial companies are marketing 
reagents or kits specially designed to help professionals in their job, mainly covering 
those diseases with higher incidence. 
From these different information sources consulted, 16 companies marketing various 
products related with genetic testing in Spain have been identified. Nine of them are 
European companies: 
- Amersham (UK) 
- Eppendorf (Germany) 
- Innogenetics (Belgium) 
- MWGAG (Germany) 
- Novagen (Germany) 
- Oncor (France) 
- Orchid Biosciences (UK) 
- Qiagen (Netherlands-Germany) 
- Roche (Switzerland)] 
and seven USA based companies: 
- Applied Biosystems 
- Axygen, Beckman Coulter 
- Bio Rad 
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Table 8 shows the diseases for which specific reagents or kits are marketed in Europe. 
Table 8. Commercially available In Vitro Tests for the detection of gene and 
chromosome alterations* 
Inborn Gene or Chromosome Alterations 
Monogenic Disorders 
Cystic Fibrosis 
Duchenne Muscular Dystrophy 
Factor V Leiden 




Polycystic Kidney Disease 
Sickle Cell Anemia 
Tay Sachs Disease 
Thalassaemia 
Friedreich's Ataxia 






































* (Source: http://www.edma-ivd.be/Classification/Final version 5.xls, access 2002-03-22 ) 
Table 9 shows a list of diseases for which commercial products are marketed in Spain 
and the companies producing them. This list has been elaborated from catalogues, 
commercial leaflets, internet web pages and telephonic contacts with company 
representatives. 
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Table 9. Companies marketing kits or reagents for genetic conditions 
Monogenic Disorders 
Alpha Thalassaemia 
Alpha 1 antitrypsin 
Beta Thalassaemia 
Cystic Fibrosis 





Sickle Cell Anemia 




Acquired Gene or Chromosome 
Alterations 
HER-2/neu 
Associated Disease (Gene) 
Predisposition to breast & ovarian cancer 
HER-2/neu(Brca1) (Brca2) 
Hypercholesterolemia, cardiovascular 
disease (Apolipoprotein E) 
Predisposition to colorectal cancer 
Predisposition to thrombosis 
Differential Diagnosis 
Familial Mediterranean Fever 




APPLIED BIOSYSTEMS; INNOGENETICS; 
SAVYON 
















4. Other topics 
Some topics not covered in the questionnaire have been explored through interviews 
with experts and are presented below. 
4.1. Access for patients to genetic testing and counselling 
The referral of a patient to genetic testing in Spain does not follow agreed protocols. 
The patient might have access to genetic testing through the regular clinical channel 
(within the health-care system) or as part of a research activity. 
On the one hand, in the clinical set-up, genetic testing follows referral by a physician. 
Usually, the referral is done by a medical specialists in a hospital requiring confirmation 
ofthe diagnosis of a genetic disease after clinical examination or biochemical testing. 
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The referral to the laboratory is not necessarily accompanied by a request for genetic 
counselling by a specialist in genetics, and the physician is him/herself responsible for 
providing the relevant information to the patient and his/her relatives. That depends on 
the existence of specific genetic units responsible for counselling of patients and his/her 
relatives and whether specific agreements between clinicians and genetic units are in 
place. 
A common concern is that a positive result of the genetic test, the confirmation of the 
genetic condition, is not always followed by the offer of genetic counselling to the 
patient and relatives. 
In this clinical set-up, the physician who orders the tests is also the person responsible 
for requiring informed consent from the patient. The labs may not have this consent 
available when performing the genetic test. 
On the other hand, many times, patients have access to genetic testing as part of 
research activities on inherited diseases. The researchers might look for patients in a 
pro-active way. The research team, usually including physicians and members of 
genetic or research units, has a research protocol that has been approved by either the 
funding institution or a specific committee in the hospital. The research protocol must 
define the scope ofthe study and procedures related to the information to be provided to 
patients post-testing. The researchers are also responsible for requiring informed 
consent from participants in the study. 
4.2 Regulatory developments in genetic testing in Spain 
The information of this section has been obtained from a consultation with Ministry of 
Health officers, key documents on the regulation of health technologies in Spain and 
interviews with experts in the field. 
Regulation and authorisation of in-vitro diagnostic medical devices are under the 
jurisdiction of the Deputy Directorate of Medical Devices, General Directorate of 
Pharmacy and Medical Devices, Ministry of Health and Consumers Affairs. Directive 
98/79/EC, on in-vitro diagnostic medical devices, has been transposed into national 
legislation by the Spanish government in the form of a Royal Decree 1662/2000, 
approved on 29 September 2000 by the Spanish Health Ministry. The provisions of this 
Decree will enter into force before the end of 2003. 
Currently, pre-market authorisation is not needed for most in-vitro diagnostic medical 
devices. An exception is testing for the detection of infection markers of a human virus 
ofthe Retroviridae family, including antigens and antibodies related to AIDS. 
Apart from that, no other specific legal regulations exist on genetic testing in Spain, 
neither at state level nor at regional level. A specific committee on genetic testing does 
not exist. Some aspects of relevance to genetic testing have been considered by other 
committees in the Ministry of Health, such as those involved in ethics, clinical trials, in-
vitro fertilisation or oncology. 
According to these data and survey results, the introduction of genetic testing in a centre 
does not require previous official authorisation in Spain, the decision being taken by 
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each hospital. The appropriate selection of tests is part of the analyst's professional 
responsibility. This could explain the multiplicity of centres and diversity of tests in 
different regions, and the lack of formal coordination platforms between centres or a 
centralised register. 
4.3 Guidelines 
We have not found specific guidelines developed in Spain in relation to genetic testing 
for specific conditions. Several university departments, hospitals and other research 
bodies are working on aspects ofthe topic, but these initiatives are not centralised or co-
ordinated in a systematic way. 
The Medical Association of Barcelona (Colegio Oficial de Médicos de Barcelona) has 
recently produced a document with recommendations for genetic testing. They stress the 
importance of informing the patients of the clinical validity of the genetic test before 
doing it. The recommendations cover relevant topics such as informed consent, privacy 
of the results, genetic counselling, participation in screening programs and ethical 
considerations . 
4.4 Rare diseases 
An specific area of concern is the accessibility to genetic testing for rare diseases. Once 
the clinical diagnosis points towards a given disease, the specialists usually contact the 
genetic unit in their region or some centre of reference at state level that indicates where 
to refer the patient for testing. According to experts opinion, an important difficulty is to 
actually reach the clinical conclusion that a patient or a family has a rare disease in 
which a genetic disorder plays an important role. 
Payment for the tests done in other centres, either in Spain or abroad, could be in some 
cases cumbersome due to the bureaucratic mechanisms, but nevertheless the tests are 
are, in their majority, carried out, as stated by experts. 
There seem to be unofficial agreements between professionals of different centres not to 
charge for testing for rare diseases for which only one or two cases a year are referred 
for testing. In those cases the workload involved is not important and the professionals 
ofthe lab usually are engaged in research networks interested in examining a number of 
patients with those rare diseases. They need cases for their studies and to have the 
experience necessary to reach and maintain expertise and proficiency in testing for those 
diseases. 
In more prevalent diseases, the workload for testing will be really relevant and labs 
either try to charge for the testing or deny access to patients referred from other centres. 
3 http://www.diariomedico.coni/edicion/noticia/0.2458.126081.00.html. last access 26 March 2002 
European Commission JRC-IPTS 23 
Genetic Testing Services for Hereditary Diseases in Spain 
Acknowledgements 
The authors wish to thank Dr. Isabel Tejada (President of the Spanish Society for 
Human Genetics) and Dr. Federico Volpini (Spanish representative in the European 
Molecular Genetics Quality Network) for their support and for the external review of 
this report. 
References 
Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, Edwards CQ, 
Kushner JP. Disease-related conditions in relatives of patients with hemochromatosis. N 
Engl J Med. 2000 Nov 23;343(21):1529-35. 
Burguera JA, Solis Ρ, Salazar A.Estimate ofthe prevalence of Huntington disease in the 
Valencia region using the capture-recapture method. Rev Neurol 1997 
Dec;25(148):1845-7. 
Darin N, Oldfors A, Moslemi AR, Holme E, Tulinius M.The incidence of mitochondrial 
encephalomyopathies in childhood: clinical features and morphological, biochemical, 
and DNA anbormalities. Ann Neurol 2001 Mar;49(3):377-83. 
Gelehrter TD; Collins FS, Ginsburg D. Medical genetics. 1.998. Williams & Wilkins. 
Baltimore. 
McCusker EA, Casse RF, Graham SJ, Williams DB, Lazarus R. Prevalence of 
Huntington disease in New South Wales in 1996. Med J Aust 2000 Aug 21;173(4): 187-
90. 
Pembrey ME; Barnicoat AJ; Carmichael B; Bobrow M; Turner G. An assessment of 
screening strategies for fragile X syndrome in the UK. Health Technology Assessment 
2001; Vol. 5: No. 7 (Executive summary). 
Percesepe A, Borghi F, Menigatti M, Losi L, Foroni M, Di Gregorio C, Rossi G, 
Pedroni M, Sala E, Vaccina F, Roncucci L, Benatti P, Viel A, Genuardi M, Marra G, 
Kristo P, Peltomäki Ρ, Ponz de Leon M. Molecular screening for hereditary 
nonpolyposis colorectal cancer: a prospective, population-based study. J Clin Oncol 
2001 Oct 1;19(19):3944-50. 
24 European Commission JRC-IPTS 
Genetic Testing Services for Hereditary Diseases in Spain 
Annex 1. Organitations involved in the area 
Asociación Española de Genética Humana, member ofthe European Society of 
Human Genetics). 
Person of contact: Dra. Isabel Tejada, (President) 
Tel. 944006154 
itej ada@hbas. osakidetza. net 
Hospital de Basurto. Bilbao. 
European Molecular Genetics Quality Network (EMQN) 
Person of contact: Dr. Victor Volpini, Spanish representative 
Tel. 932607775 
vvolpini@iro.es 
Institut Recerca Oncológica. Barcelona 
Sociedad Española de Genética, Sección de Genética Humana 
Person of contact: Joan Fibla Palazón 
Tel: +34 973 702 403 Fax: +34 973 702 426 
joan.fibla@cmb.udl.es 
Facultad de Medicina. Universidad de Lleida 
Sociedad Española de Endocrinología Pediátrica, Working Group on Molecular 
Genetics in Paediatric Endocrinology 
Person of contact: Dr. Luis Castaño, coordinator 
Tel.: 946006376 
lcastano@hcru.osakidetza.net 
Hospital de Cruces 
Asociación Española de Pediatría, Sección de Genética Clínica y Dismorfología 
Enrique Galán, President ofthe section 
924230400 ext 287. 
egalan@ctv.es 
Hospital Materno Infantil de Badajoz. 
Sociedad Española de Errores Innatos del Metabolismo 
Person of contact: Guillen Pintos 
gpintos@ns.hugtip.scs.es 
Rare Diseases Programme in the Spanish Health Ministry 
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Registro Español de Malformaciones Congénitas 
Person of contact: María Luisa Martínez Frias 
Telephone: 91 394 15 86 
luisama@eucmos.sim.ucm.es 
ISCHI 
Federación Española de Enfermedades Raras (FEDER). Member ofthe European 
Organisation for Rare Disease (http://www.eurordis.org) 
Address: C/ Enrique Marco Dorta, 6. Local. 41018 Sevilla. Spain. 
Telephone number: +34 954 98 98 92 
Help line:+34 902 18 17 25 
Fax number: +34 954 98 98 93 
E-mail address: f.e.d.e.r@teleline.es 
Date of Start: 19 April 1999 
President: Moisés Abascal Alonso 
PARD I Coordinator: Rosa Sanchez de Vega 
Sociedad Española Neurología http://www.sen.es/recursos/genet/genetica.html 
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Annex 2. Questionnaire sent to the centres and laboratories 
Encuesta sobre la oferta de diagnóstico genético 
para enfermedades hereditarias en España 
La presente encuesta es parte del estudio "Prospective study on Genetic Testing 
Services quality assurance and harmonisation in EU" del Institute for Prospective 
Technological Studies, Joint Research Centre de la Comisión Europea. Esta encuesta 
está siendo realizada por la Agencia de Evaluación de Tecnologías Sanitarias de 
Andalucía por encargo de esa institución. 
El objetivo de esta encuesta es obtener información actualizada sobre los centros que 
realizan algún tipo de prueba de diagnóstico genético para enfermedades hereditarias en 
España. 








Type of centre: 
(sanitario, universitario,... ; de propiedad pública, privada, concertado,...) 
1.- ¿Realiza su centro algún tipo de prueba de diagnóstico genético de enfermedades 
hereditarias? (SI ó NO) 
En caso de no realizar en la actualidad ese tipo de pruebas pero sí en el pasado no tiene 
que contestar el resto de preguntas de esta encuesta. Simplemente díganos que pruebas 
realizaban y cuando dejaron de hacerlas. 
2.- De las siguientes listas con diversas enfermedades hereditarias, señale aquellas para 
cuales de ellas disponen o realizan pruebas genéticas en su centro y el número de 
pruebas que ha realizado el pasado año para cada enfermedad. 
En caso de realizar alguna prueba que no aparezca en las tablas siguientes escríbalo a 
continuación o en la última fila de cada tabla. 
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PATOLOGIAS NEUROLÓGICAS 
Ataxias dominantes (ADCAS) SCA1; SCA2 (E. de Machado); 
SCA3; SCA6; SCA7; SCA8; SCA9; SCAIO; SCA12 
Ataxia Friedrich (X25) 
Atrofia dentato-rubal palidoluisiana (Dentatorubro-
palidoluisiana) 
Atrofia muscular espinal (Werdnig-Hoffmann y Kugelberg-
Welander) (SMN) 
Atrofia muscular espino-bulbar Enfermedad de Kennedy. (AR, 
exón 1) 
Demencia frontotemporal (tau) (detección de mutacions) / 
Parálisis supranuclear progresiva tau (genotipo polimorfico) 
Distrofia facio-escapulo-humeral 
Distrofias maculares dominantes (gen DS/periferina) 
Distrofia miotónica de Steinert 
Distonia de Torsión (DYTl) 
Distrofia muscular de Duchenne/Becker 
E. Hirschsprung 
E. Alzheimer (Presenilina 1, APP, APÕE) 
E. Huntington 
E. Norrie 
Neurofibromatosis tipo 1 
Neuropatía Charcot-Marie-Tooth 
Análisis de ligamiento de las NFl y NF2 
Neuropatía óptica de Leber 
Neuropatía por sensibilidad a la presión 
Paraplejla espástica familiar 
Parkinson (Parkin, a-sinucleina) 
Retraso mental asociado a la fragilidad tipo FRAXE (FMR2) 
Retraso Mental (GDI 1) 
Retraso Mental (PAK3) 
S°. Angelman 
S°. Prader Willi 
S°. Smith-Magenis 
S°. Rett 
S°. de Williams-Beuren (LOH , FISH) (ΑΤΡ7Β) 
S X-Frágil (FMRl) 
OTRA(S) ESPECIFICAR 
SI/NO 
(N° de pruebas en 
2001) 
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Trombofilia Hereditaria (Mut. G169IA del gen del factor V 
Leiden) (Mut G20210A del gen de la protrombina 
OTRA(S) ESPECIFICAR 
SI/NO 
(N° de pruebas el 
año 2001) 
CÁNCER HEREDITARIO 
Cáncer mama (BCRA1 y BCRA2) 
CK-19 (Células circulantes, cel epitelial, mama, ovario) 
GST mu (colon, vejiga) 
K-RAS (CODON 12, 13)(pulmón, colon, ovario, laringe) 
PSA (cel. Circulantes sangre, ca. próstata) 
Ρ53 EXONES 4,5,6,7,8 (Pulmón, Mama, Ovario, Endomet.) 
E. Li-Fraumeni (p53) 
Feocromocitoma familiar 
Melanoma familiar (pl5, pl9,CDK4) 
Melanoma familiar (pió) 
MENI 
Neoplasia endocrino múltiple MEN2A 
Neoplasia endocrino múltiple MEN2B 
Poliposis adenomatosa familiar 
E. Von Hippel Lindau 
OTRA(S) ESPECIFICAR 
SI/NO 
(N° de pruebas el 
año 2001) 
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PATOLOGIAS METABÓLICAS 
Acidemia glutárica tipo I 
Acidemia propiónica 
Adrenoleucodistrofia ligada al Χ 
Déficit de Acil-CoA deshidrogenasa de cadena media ( MCAD ) 
(Mutación K304E) 
Defecto familiar de ApoB 
Déficit de 21 -hidroxilasa 
Déficit de 11-beta-hidroxilasa 
Déficit de 17-alfa-hidroxilasa 
Déficit de 3-beta-hidroxiesteroide-deshidrogenasa 
Déficit de alfa-1-antitripsina 
Def. Carnitina Palmitoil Transferasa II (Mutación Y628S) 
Déficit de GH 
Déficit de hidroxiacil-CoA deshidrogenasa de 
Cadena larga ( LCHAD) 
Diabetes tipo MODY. (GK, HNF1) 
E. Gaucher 
E. de Hurler 
E. de Morquio Β 
E. Sanfilippo A 




Hiperaldosteronismo primario tipo I 
Hiperplasia suprarrenal congénita 
Leucodistrofia Metacromática y pseudodeficiència 
Arilsulfatasa A 
Ligamiento a LDL (Hipercolesterolemia) 
S° de insensibilidada la GH 
OTRA(S) ESPECIFICAR 
SI/NO 
(N° de pruebas el 
año 2001) 





(N° de pruebas 
el año 2001) 
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OTRAS PATOLOGÍAS 
Azoospermia y oligospermia (Microdeleciones cr. Y) 
Acondroplasia/Hipocondroplasia (FGFR3 ) 
Coroideremia 
Fibrosis Quística (CFTR) 
Cistinuria 
Déficit de Hormona de Crecimiento. (GH) 
Enfermedad celiaca 
Enfermedad de Norrie (NDP) 
Enfermedad de Wilson (ATP7B) 
Factor V de Leyden 
Gen de protrombina 
Gen SRY (Alteraciones del desarrollo sexual) 
Fiebre Mediterránea Familiar 
Hemocromatosis (HFE) 
Hematuria familiar benigna 
Hipertensión familiar 
Hiper/Hipotiroidismo familiar, (receptor de TSH) 
Hipoplasia adrenal congénita 
Homocistinuria 
Holoprosencefalia 
Ligamiento a NPC1 
Lipofuscinosis Neuronal Ceroidea /Batten disease: 




Poliendrocrinopatia autoinmune tipo 1 
Poliquistosis renal dominante tipo 1 
Poliquistosis renal recesiva tipo 2 
Raquitismo vitamino-D-resistente 
Resistencias Androgénicas: Síndrome de Morris, 
Síndrome de Reifenstein (AR exones 2-8) 
Retinosis pigmentaria 
Retinosis pigmentaria ligada al X 
Retinosis pigmentaria autosómica dominante (genes 
RHO y RDS) 
Retinosquisis 
SI/NO 
(N° de pruebas el 
año 2001) 
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Sindrome de Alport (autosómico dominante, autosómico recesivo; 
ligado al cromosoma Χ) 
Sorderas esporádicas y autosómicas recesivas 
(Gen de la Conexina 26) 
S. Di George 
OTRA(S) ESPECIFICAR 
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3.- ¿Ha pasado su centro o servicio por un proceso de acreditación específico para la 
realización de esas pruebas de diagnóstico genético de enfermedades hereditarias? (SI ó 
NO): 
En caso afirmativo: ¿qué institución les ha acreditado? 
4.- ¿Disponen de algún laboratorio de referencia para control de calidad de esas 
pruebas? (SI ó NO): 
En caso afirmativo escriba el nombre de dicho laboratorio: 
y señale con qué frecuencia realizan esos controles de calidad: 
5.- ¿Es el suyo un centro de referencia para otros centros que le remiten muestras para 
pruebas genéticas de alguna enfermedad hereditaria a nivel autonómico o estatal? 
6.- ¿Tienen un laboratorio u otros laboratorios de referencia para enviar muestras a 
analizar con tests de los que no disponen en su laboratorio? (SI ó NO): 
En caso afirmativo escriba el nombre de dicho(s) laboratorio(s): 
7.- ¿Hay algún caso en que sean los propios pacientes quienes financien los costes de las 
pruebas o son siempre financiadas directamente por la institución con cargo a fondos 
públicos?: 
¿qué porcentaje de pruebas estima que son de financiación privada? 
8.- ¿Exigen la firma de un documento de consentimiento informado antes de la 
realización de las pruebas? (SI ó NO): 
9.- ¿Tienen una política expresa para garantizar la privacidad de los datos que analizan? 
(SI ó NO): 
Si quiere añadir o sugerir alguna otra cosa, hágalo a continuación. 
Envíenos por favor este archivo a la siguiente Address: jrueda@euskalnet.net. 
MUCHAS GRACIAS POR SU COLABORACIÓN. 
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Annex 3. Introductory letter attached to the questionnaire 
Estimad® Dr/a: 
Adjunto le remito un documento en formato Word con una encuesta sobre el uso de 
pruebas de diagnóstico genético de enfermedades hereditarias en España. Forma 
parte del estudio "Prospective study on Genetic Testing Services quality assurance 
and harmonisation in EU" del Institute for Prospective Technological Studies, Joint 
Research Centre de la Comisión Europea. Esta encuesta está siendo realizada por la 
Agencia de Evaluación de Tecnologías Sanitarias de Andalucía por encargo de esa 
institución. 
Rellenarla le llevará entre 10 y 15 minutos. Contéstela directamente en el archivo de 
texto y envíenoslo por E-maíl. 
Esta encuesta va a ser enviada a todos los centros sanitarios o universitarios de los 
que tenemos conocimiento que realizan algún tipo de prueba de diagnóstico genético. 
A continuación tiene una lista de los centros que tenemos localizados. Si conoce algún 
otro centro, en especial de su comunidad autónoma, que no esté recogido en la lista 
anterior díganoslo. 
Si tiene cualquier duda, no dude en ponerse en contacto con nosotros. 
Dr. Jose Ramón Rueda, tf.: 944102684 
Dr. Eduardo Briones, tf.: 955006841 
Muchas gracias por su colaboración. 
ANDALUCÍA: 
Hospital Reina Sofía. Córdoba 
Hospital Virgen de las Nieves. Granada 
Hospital Universitario. Granada 
Centro de Estudios Genéticos de Andalucía. Granada 
Hospital Materno-lnfantil Málaga 
Hospital Universitario Virgen de la Macarena Sevilla 
Hospital Universitario Virgen del Rocío Sevilla 
ARAGÓN: 
Hospital Clínico Universitario. Zaragoza 
Hospital Miguel Servet. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
ASTURIAS: 
Hospital Central de Asturias. Oviedo 
BALEARES: 
Hospital Son Dureta. Palma de Mallorca 
Centro de Detección Precoz y Consejo Genético. Palma de Mallorca 
CANARIAS: 
Unidad de Genética Hospital Materno Infantil. Las Palmas de Gran Canaria 
Facultad de Medicina. La Laguna. Tenerife 
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CANTABRIA: 
Hospital Valdecílla. Santander 
CASTILLA-LA MANCHA: 
Hospital Nacional de Parapléjicos. Toledo 
Hospital General de Segovia. Segovia 
CASTILLA-LEON: 
Instituto de Biología y Genética Molecular. Facultad de Medicina. Valladolid 
CATALUÑA: 
H.Materno Infantil Vali d'Hebron. Barcelona 
H. la Santa Creu i Sant Pau. Barcelona 
Hospital Clinic. Barcelona 
Hospital San Juan de Dios. Barcelona 
Instituto Bioquímica Clínica. Barcelona 
Centro Patología Celular y Diagnóstico Prenatal Barcelona 
Prenatal Diagnosis Barcelona 
Laboratorio de Análisis Dr. Echevarne Barcelona 
Instit. Resercha Oncológica. Hospitalet 
Consorci Hospitalarl ParcTauli. Sabadell 
Laboratorio Cerba.S.A.E. Sabadell 
C. A. VASCA: 
Hospital de Basurto. Bilbao 
Hospital de Cruces. Baracaldo 
Policlínica Guipúzcoa San Sebastián 
Instituto Neurobiologia Molecular. San Sebastián 
EXTREMADURA: 
Hospital Materno- Infantil. Badajoz 
GALICIA: 
H. Materno-lnfantíl Teresa Herrera. La Coruna 
Centro Oncológico de Galicia. La Coruna 
Hospital General de Galicia & Hospital Gil Casas. Santiago de Compostela 
Hospital de Conxo. Unidad de Medicina Molecular (INGO). Santiago de Compostela 
MADRID: 
Fundación Jiménez Díaz. Madrid 
Hospital Ramón y Cajal. Madrid 
Hospital La Paz. Madrid 
Hospital 12 Octubre. Madrid 
Hospital Clínico San Carlos. Madrid 
Hospital de Móstoles. 
Centro Diagnóstico Enfermedades Moleculares. Dpto. Biología Molecular. UAM. 
Centro Nacional Investigaciones Oncológicas. Majadahonda 
MURCIA: 
Hospital Virgen de la Arrixaca. Murcia. 
NAVARRA: 
Hospital Virgen del Camino Pamplona 
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Dpt.Genética. Universidad Navarra Pamplona 
VALENCIA: 
Universität dAlicant. Alicante 
Hospital La Fe. Valencia 
Dpto. Patología. Universidad de Valencia. 
Institut de Genètica Mèdica i Molecular (IGEM). C. Virgen del Consuelo Valencia 
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Annex 4. List of centres 
ANDALUCÍA: 
Hospital Virgen del Rocío 
Unit: Genética Médica y Diagnóstico Prenatal 
Contact person: Guillermo Antiñolo Gil 
Address: Avda. Manuel Siurot s/n. 41013 Sevilla 
Telephone: 955 01 2778 
E-mail: gantinolo@hvr.sas.junta-andalucia.es 
Type of centre: public hospital 
Hospital Virgen de la Macarena 
Unit: Biología Molecular 
Contact person: Miguel Lucas 
Address: Avda Dr. Fedriani S/N 41071. Sevilla 
Telephone: 955008114 
E-mail: lucas@us.es 
Type of centre: public hospital 
Hospital San Cecilio 
Unit: Bioquímica. 
Contact person: José Antonio Gómez Capilla. 
Address: Departamento de Bioquímica y Biología Molecular. Facultad de Medicina. 
Avd/ Madrid s/n. 18012. Granada. 
Telephone: 958 243524/958023107/958243517 
E-mail:jgomez@ugr.es 
Type of centre: public hospital 
Hospital Virgen de las Nieves 
Unit: Laboratorio Genética. 
Contact person: Matías Pérez 
Address: Avda. Fuerzas Armadas. 
13014 Granada 
Telephone: 958020011 
E-mail :mperez@hvn.sas. cica.es 
Type of centre: public hospital 
Hospital Carlos Haya 
Unit: Servicio de hematología y hemoterapia 
Contact person: Dr. Antonio Jimenez Velasco 
Address: Avenida Carlos Haya s/n. 29010. Málaga 
Telephone: 952645808 
E-mail: jimeneza@hch.sas.junta-andalucia.es 
Type of centre: public hospital 
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Unit: Laboratorio - Genética. 
Arroyo de los Ángeles, s/n. 29011-Málaga 
952304400. Dr. Marceliano Herránz. herranz@hch.sas.cica.es 
Laboratorio. Inmunología: Antonio Alonso aalonso@hch.sas.iunta-andalucia.es 
Anatomía Patológica: Dolores Bautista, dbautista@hch.sas.junta-andalucia.es 
952645838 
NBT DIAGEN. CENTRO DE DIAGNOSTICO GENETICO 
Contact person: Dr. Narain 
Address: C/ Educardo Rivas 2-4. 41018 Sevilla 
Telephone: 954575508 
E-mail: narain@newbiotechnic.com 
Type of centre: private laboratory 
ARAGÓN: 
Hospital Miguel Servet 
Unit: Genética Médica 
Contact person: Manuel Tamparillas Salvador 
Address: Paseo Isabel La Católica 1 y 3. 50009 Zaragoza 
Telephone: 976765500 Ext 3150 
E-mail: mtamparilla@hmservet.insalud.es 
Type of centre: public hospital 
Centro de Analisis Genéticos C.A.G.T. 
Unit: Genetica Clinica. Genética Molecular y Citogenètica 
Contact person: Dra. Ana Ma Palacio de Parada. Dra. Pilar Madero Barrajón 
Address: C/ Teresa de Jesús 45-47. 50006- Zaragoza 
Telephone: 976-55 64 84. Fax: 976- 30 69 10 
E-mail: e-mail: cagt@arrakis.es 
Type of centre: Private laboratory 
Universidad de Zaragoza 
Unit: Bioquímica y Biología Molecular 
Contact person: Julio Montoya 
Address: Miguel Servet 177 
Telephone: +34-976761640 
E-mail: jmontoya@posta.unizar.es 
Type of centre: public university 
Unit: Depart. Bioquímica, Biologia Molecular y Celular 
Contact person: Miguel Pocoví Mieras 
Address: Departamento Bioquímica, Biología Molecular y Celular. Fac. Ciencias. 
Universidad de Zaragoza. Campus Plaza San Francisco sn. 50009 Zaragoza 
Telephone:34-976-761283 
E-mail: mpocovi@posta.unizar.es 
Type of centre: public university 
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ASTURIAS 
Hospital Central de Asturias 
Unit: Genética Molecular 
Contact person: Dr. Eliecer Coto García 
Celestino Villamil s/n 33006 Oviedo 33006 - OVIEDO - SPAIN 
Telephone: 985.10.79.68 
E-mail: ecoto@hcas.insalud.es 
Type of centre: public hospital 
BALEARES 
Hospital Son Dureta. Mallorca 
Unit: Genética 
Contact person: Damián Heine Suñer 
Address: Sección de Genética, H. Universitario Son Dureta. Avda. Andrea Doria 55. 
Palma de Mallorca 07014 
Telephone: 971-175147 
E-mail: dheine@hsd.es 
Type of centre: public hospital 
CANARIAS 
Hospital Materno-Infantil de Canarias. Las Palmas 
Unit: Laboratorio de Genética Molecular 
Contact person: Dr. Miguel Fernández-Burriel Tercero 
Address: Avda. Marítima del Sur s/n 
35016-Las Palmas de Gran Canaria 
Telephone: 928444790 
E-mail: m.fernandez.012@recol.es 
Type of centre: public hospital 
Hospital Universitario de Canarias 
Unit: Unidad de Investigación 
Contact person: Eduardo Salido Ruiz 
Address: Ofra-La Cuesta s/n. E-38320 Tenerife 
Telephone: 922-319338 
E-mail: esalido@ull.es 
Type of centre: public hospital 
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CANTABRIA 
Hospital Marqués de Valdecilla 
Unit: Inmunología 
Contact person: Francisco Leyva-Cobián 
Address: Avenida de Valdecilla, s/n. 39008-Santander 
Telephone: 942-202549 
E-mail: fleyvaco@sarenet.es 
Type of centre: public hospital 
Unit: Neurología 
Contact person: José Berciano 
Telephone: 942-202520 
E-mail: neuro@humv.es 
CASTILLA LA MANCHA 
Hospital Virgen de la Salud. Toledo 
Unit: Genética 
Contact person: Pedro Martínez 
Address: Laboratorio de Genética. Hospital Nacional de Parapléjicos. Finca de la 
Peraleda s/n. 45071 Toledo 
Telephone: 925-24 77 37 
E-mail: pmartinez@cht.insalud.es 
Type of centre: public hospital 
CASTILLA-LEON 
Instituto de Biología y Genética Molecular 
Unit: Unidad de Diagnóstico Genético y Perinatal 
Contact person: Juan José Telleria Orriols 
Address: Avda. de Ramón y Cajal 7; 47005 Valladolid 
Telephone: 983 423 189 
E-mail: telleria@med.uva.es 
Type of centre: public university 
Universidad de Salamanca 
Unit: Unidad de Medicina Molecular 
Contact person: Rogelio González Sarmiento 
Address: Facultad de Medicina. Avda. Campo Charro s/n 37007 Salamanca 
Telephone: 9023294553 
E-mail:gonzalez@usal.es 
Type of centre: public university 
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CATALUNA: 
Hospital Clínico de Barcelona 
Unit: Genética 
Contact person: Dr. Rafael Oliva 
Address: Villarroel 170, 08036 Barcelona 
Telephone: 93 2275510 
E-mail: oliva@medicina.ub.es 
Unit: Centro de Diagnòstico Biomédico 
Contact person: Josep Oriola 
Telephone: 932275400 
E-mail: joriola@clinic.ub.es 
Type of centre: public hospital 
Institut de Bioquímica Clínica. Clínic-Corporació Sanitària 
Contact person : Dra. Teresa Pàmpols 
Address : Institut de Bioquímica Clínica . Calle Mej ia Lequerica 
s/n, Edificio Helios III, Planta baja . 08028 Barcelona 
Telephone : 03 2275672 
E-mail : tpampols@clinic.ub.es 
Type of centre : public centre 
H. la Santa Creu i Sant Pau 
Unit: Servicio de Genética 
Contact person: Montserrat Baiget 
Address: Padre Claret 167. 08025 Barcelona 
Telephone: 93-2919361 
E-mail: mbaiget@hsp.santpau.es 
Type of centre: public hospital 
Hospital Valle Hebron 
Unit: Centro de Investigación en Bioquímica y Biologia Molecular 
Contact person: Dr. Antonio Luis Andreu Periz 
Address: P. Valle Hebron 119-129. 08035 Barcelona 
Telephone: 934894057 
E-mail: tandreu@hg.vhebron.es 
Type of centre: public hospital 
Unit: Unidad Investigación Endocrinología y Nutrición Pediátricas 
Contact person: Dra. Laura Audi 
Telephone: 934894030 
E-mail: laudi@cs.vhebron.es 
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Institut Reserca Oncològica 
Unit: Centro de Genética Médica y Molecular. 
Personas de contacto: Virginia Nunes (Jefe de Departamento), V. Volpini(representante 
español en el EMQN) 
Address: Gran vía s/n km 2,7. Hospitalet del Llobregat 08907, Barcelona 
Telephone: 93 2607427 
E-mail: vnunes@iro.es, vvolpini@iro.es 
Type of centre: Research centre, private 
Hospital Sant Joan de Déu, Barcelona 
Unit: Sección Genética, Unidad Genética Molecular 
Contact person: Eugenia Monrós 
Address: Pss. Sant Joan de Déu 2, 08950 Esplugues 
Telephone: 93 253 2103 
E-mail: emonros@hsjdbcn.org 
Type of centre: private hospital 
Hospital del Mar - Facultad de Ciencias de la Salud (Universität Pompeu Fabra) 
Unit: Laboratorio de Citogenètica y Biología Molecular (Dept. Patología) Unidad de 
Genética 
Personas de contacto: Francese Solé. Luis Pérez Jurado 
Address: Paseo Marítimo 25-29. 08003 Barcelona 
Telephone: 93-2483035 
E-mail: e0037@imas.imim.es / luis.perez@cexs.upf.es 
Type of centre: public hospital and public university 
Corporación Parc Taulí. UDIAT-CD 
Unit: Laboratorio, Genética 
Contact person: Miriam Guitart 
Address: Laboratorio. UDIAT-CD. Corporación Parc Taulí. 
Parc Taulí s/n. 08208 Sabadell.(Barcelona) 
Telephone:937231010 Ext.26111 
E-mail: mguitart@cspt.es 
Type of centre: public hospital 
Laboratorio de Análisis Dr. Echevarne 
Unit: Genética y Medicina Molecular 
Contact person: Dr. José Ignacio Lao Villadóniga 
Address: Provenza 312 (bajos). 08037 Barcelona 
Telephone: 93-4964456 
E-mail: jilao@echevarne.com 
Type of centre: private laboratory 
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Centro de Patologia Celular 
Contact person: Dra. Marta Carrera 
Address: C/ Londres, n° 6, 08029 Barcelona 
Telephone: 93 322 88 06 
E-mail: mca@sabater-tobella.com 
Type of centre: private laboratory 
EXTREMADURA: 
Hospital Materno Infantil de Badajoz 
Unit: Unidad de Genética 
Contact person: Dr. Enrique Galan Gomez 
Address: c/ Damián Téllez Lafuente s/n , Badajoz 06004 
Telephone: 924-230400, EXT 287 (consulta), 458-459 (laboratorio) 
E-mail: egala@ctv.es 
Type of centre: public hospital 
GALICIA: 
Hospital de Conxo, FINGO 
Unit: Unidad de Medicina Molecular 
Contact person: Francisco Barros o Lourdes Loidi 
Address: Hospital de Conxo, Rúa Ramón Baltar SN. 15706 Santiago de Compostela 
Telephone: 981 951 888 
E-mail: apimlbar@usc.es o lloidi@usc.es 
Type of centre: public hospital 
Centro Oncológico de Galicia. 
Unit: laboratorio de Genética y Radiobiología 
Contact person: A Mosquera 
Address: Avda. Montserrat s/n 15009 A Coruna 
Telephone: 981287499 ext 292 
E-mail: genetica@cog.es 
Type of centre: public hospital 
Hospital Clinico Universitario de Santiago 
UnitGenética Médica 
Contact persomDra.A.Ansede 
Address:C/Houpana s/n Santiago 
Telephoned 1950045 
E-mail:branas@mixmail.com Type of centre: Hospital Universitario Public 
Type of centre: public hospital 
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H. Juan C añalejo 
Unit: Hematologia y hemoterapia 
Contact person: Dr. Javier Batlle Fonrodona. 
Address: Edificio H. Teresa Herrera. Avda. Pasaje s/n. 15006 A CORUNA 
Telephone: 981 178000 (Ext 21113; 21115) 
E-mail: jbatlle@canalejo.cesga.es 
Type of centre: public hospital 
S. Genética. Berta Rodríguez 
Telephone: 981178000 berta_rodriguez@canalejo.org 
MADRID: 
Hospital Universitario La Paz 
Unit: Unidad de Genética Molecular. Servicio de Bioquímica 
Contact person: Jesús Molano Mateos 
Telephone: 917277381 
E-mail:jmolano@hulp. insalud.es 
Address: Paseo de la Castellana 261 ; 28046 Madrid 
Type of centre: public hospital 
Unit: Unidad de Inmunología 
Contact person: Ma Cruz García Rodríguez 
Telephone: 91 7277095, 91 7277238 
E-mail: mcruzgarcia@hulp.insalud.es 
Hospital Gregorio Marañón 
Unit: Servicio Bioquímica. Laboratorio de Diagnóstico Molecular. 
Contact person: Dra Begoña Ezquieta 
Address: c/ Doctor Esquerdo 46. 28007 Madrid 
Telephone: 915868466 
E-mail: bezquieta@airtel.net 
Type of centre: public hospital 
Fundación Jiménez Díaz. Madrid 
Unit: Genética 
Contact person: Carmen Ayuso // Carmen Ramos 
Address: Av. Reyes católicos n° 2. 28040 Madrid 
Telephone: 91/ 5446903 - 91/5504872 
E-mail: Cayuso@fjd.es 
Type of centre: private hospital 
44 European Commission JRC-IPTS 
Genetic Testing Services for Hereditary Diseases in Spain 
Hospital Clinico San Carlos 
Unit: Genética 
Contact person: Dra Lautre Ecenarro 
Address: Ciudad Universitaria, s/n Madrid. 
Telephone: 913303023 
E-mail: mlautre@hcsc.insalud.es 
Type of centre: public hospital 
Unit: Imunologia y Oncología Molecular 
Contact person: Trinidad Caldés 
Telephone: 913303348 
E-mail: tcaldes@hcsc.es 
Hospital 12 Octubre 
Centro: Hospital Universitario 12 de Octubre 
Unit: Centro de Investigación 
Contact person: Joaquín Arenas 
Address: Avda de Córdoba km 5.4. 28041 Madrid 
Telephone: 91-390-8411 
E-mail: jarenas@hl20.es 
Type of centre: public hospital 
Hospital Ramón y Cajal 
Centro: Hospital Ramón y Cajal 
Unit: Unidad de Genética Molecular 
Contact person: Felipe Moreno 
Address: Carretera de Colmenar km 9,100. 28034 Madrid. 
Telephone: 913368541 
E-mail: fmoreno@hrc.insalud.es 
Type of centre: public hospital 
Centro de Diagnóstico de Enfermedades Moleculares 
Contact person: Prof. M. Ugarte 
Address: Dpto. Biología Molecular, Facultad de Ciencias, Universidad Autónoma de 
Madrid, 28049 Madrid 
Telephone: 91 3974589 
E-mail: cedem@cbm.uam.es 
Type of centre: public university 
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Centro Nacional Investigaciones Oncológicas (CNIO) 
Unit: Dpto Genética Humana 
Contact person: Javier Benítez 
Address: Melchor Fdez. Almagro 3 Madrid 28029 
Telephoned 12246965 
E-mail :jbenitez@cnio.es 
Type of centre: public research centre 
Centro de Investigación sobre Anomalías Congénitas (CIAC), Instituto de Salud 
Carlos III. Ministerio de Sanidad y Consumo. Madrid. 
Unit: Estudio Colaborativo Español de Malformaciones Congénitas 
Contact person: Profa. Dra. María Luisa Martínez-Frías 
Address: ISCHI. CIAC Calle, Sinesio Delgado, 6. Madrid 
Telephone: 91 394 15 86 
E-mail: luisama@med.ucm.es 
Type of centre: public research centre 
MURCIA 
Centro de Bioquímica y Genética Clínica 
UnitUnidad de Genética Molecular 
Contact person: Guillermo Glover 
Address: Centro de Bioquímica y Genética Clínica. Labs Pabellón General. Hospital 
Virgen Arrixaca. 30120. El Palmar (Murcia) 
Telephone:968 88 98 60 
E-mail:guillermo. glover@carm.es 
Type of centre: public centre 
NAVARRA 
Hospital Virgen del Camino Pamplona. 
Unit: Genetica 
Contact person: Alberto Valiente 
Address: Irunlarrea,4; 31008; Pamplona 
Telephone: 948/429991 
E-mail: avalienm@cfnavarra.es 
Type of centre: public hospital 
Clínica Universitaria. Pamplona 
Unit: Laboratorio de Biotecnología y Genómica 
Contact person: Dr. Jesús García-Foncillas 
Address: Avda Pio XII, 36. 31008-Pamplona 
Telephone: 948296792/948296292. 
E-mail: jgfoncillas@unav.es 
Type of centre: private hospital 
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PAIS VALENCIA 
Hospital Universitario La Fe. Valencia 
Unit: Unidad de Genética y Diagnóstico Prenatal 
Contact person: José Ma Millán Salvador 
Address: Avda. Campanar, 21 Valencia 46009 
Telephone: 96-3987370 
E-mail: chema_millan@yahoo.es 
Type of centre: public hospital 
Facultad de Medicina Valencia 
Unit: Departamento de Patologia 
Contact person: Antonio Pellín Pérez 
Address: Departamento de Patologia. Facultad de Medicina 
Blasco Ibáñez, 17. Valencia 46010 
Telephone: 969 3864145 
E-mail: Antonio.Pellin@uv.es 
Type of centre: public university 
Facultad de Medicina Alicante. Universidad Miguel Hernández. 
Unit: Unidad de Genética y Diagnóstico Prenatal. Departamento de Pediatría. 
Contact person: Francisco Galan Sanchez 
Address: Campus de San Juan. Apdo. de correos 18. 03550 - San Juan (Alicante) 
Telephone: 96-5919433; Fax: 96-5919429 
E-mail: fm.galan@umh.es 
Type of centre: public university 
Análisis Genéticos ANCOR S.L. 
Contact person: Andrés Corno 
Address: Avda Eusebio Sempere 22, 03003-Alicante 
Telephone: 965 13 57 43-659 437 825 Fax :965 13 45 35 
E-mail : ancor@vianwe.com 
Type of centre: private laboratory 
Institut de Genética Mèdica i Molecular, IGEM Valencia 
Contact person: Javier García Planells 
Address: Clínica Virgen del Consuelo. C/ Callosa d'Ensarriá, 12. Valencia 46007. 
Telephoned 317 78 00/96 317 78 21 
E-mail: info@igem.es 
Type of centre: private laboratory 
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PAIS VASCO 
Hospital de Basurto 
Unit: UNIDAD DE GENETICA (Laboratorio de Genética Molecular) 
Contact person: Dra. Ma Isabel TEJADA 
Address: Avda. Montevideo 18 /48013-BILBAO 
Telephone: 944006154 
E-mail: itejada@hbas.osakidetza.net 
Type of centre: public hospital 
Hospital de Cruces 
Unit: Unidad de Investigación 
Contact person: Luis Castaño 
Address: Plaza de Cruces S/N. 48903 Baracaldo. Vizcaya 
Telephone: 946006376 
E-mail: lcastano@hcru.osakidetza.net 
Type of centre: public hospital 
Hospital Donostia 
Unit: Genética 
Contact person: Dra. Ana María Cobo Esteban 
Address: Paseo Dr Begiristain s/n San Sebastian 20014 
Telephone: 943 007301 
E-mail: anacobo@chdo.osakidetza.net 
Type of centre: public hospital 
Unit: Unidad Experimental 
Contact person: Adolfo López de Munain 
Telephone: 943 00 70 61 
E-mail: uniexpe2@chdo.osakidetza.net 
Type of centre: sanitario publico 
Policlínica Gipuzkoa 
Unit: Genética Molecular 
Contact person: Dra. C. Vidales 
Address: Paseo de Miramon, 174 
20009- San Sebastián 
Telephone: 943002837 
E-mail : biomol@policlinicagipuzkoa.com 
Type of centre: private hospital 
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RIOJA 
Hospital San Millán. Logroño 
Centro: Hospital "San Millán- San Pedro" 
Unit: Laboratorio Central 
Contact person: Luis Borque ó Fernando Iguaz 
Address: C/Autonomía de La Rioja, 3. 26004 Logroño 
Telephone: 941-294500 Ext. 553 , 551, 2003 
E-mail: lborque@arrakis.es y figuazp@nexo.es 
Type of centre: public hospital 
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(N/S when not 
specified by 
the centre) 
Alzheimer disease (Presenilina 1, 
APP, APOE) 
Hospital Clínico Barcelona 300 
H. Central de Asturias 220 
H Virgen del Camino 125 
U. Salamanca 50 
Η. Valdecilla 25 
Centro de Bioquímica y Genética Clínica Murcia APOE 
25 
H. Miguel Servet 23 
Η. Universitario Tenerife 20 
Η. Macarena Sevilla 20 
Clínica Universitaria Pamplona 15 
Laboratorio de Análisis Dr. Echevarne Barcelona 9 
Centro de Análisis Genéticos. Zaragoza 7 
H. Conxo. Santiago 3 
NBT DIAGEN Sevilla N/S 
ANCOR Alicante N/S 
Amiliodean familiar polineuropathy H. Son Pureta Mallorca 10 
Aneuplodies by QFPCR Laboratorio de Análisis Dr. Echevarne Barcelona 460 
Angelman syndrome Hospital Sant Joan de Déu, Barcelona 44 
H. La Fe. Valencia 35 
H. Miguel Servet 35 
F. Jiménez Díaz 25 
H. Son Dureta Mallorca 25 
H. Pare Taulí Barcelona 23 
H. Materno Infantil Badajoz 20 
H. Central de Asturias 13 
H Virgen del Camino 11 
Centro de Bioquímica y Genética Clínica Murcia 5 
Hospital Clínico Universitario Santiago 8 
Centro Oncológico de Galicia. A Coruna 4 
H. Virgen de la Salud Toledo 4 
IGEM Valencia 2 
H. del Mar - UPF Barcelona 2 
Laboratorio de Análisis Dr. Echevarne Barcelona 2 
H.Universitario Las Palmas 1 
Centro Investigación Anomalías Congénitas Ν / ς 
Madrid. 
Η. Virgen de las Nieves. Granada N/S 
H. V. Rocío Sevilla N/S 
CADASIL Centro de Análisis Genéticos. Zaragoza 1 
Charcot-Marie-Tooth neuropathy IRO Barcelona 313 
Hospital Sant Joan de Déu, Barcelona 71 
H. La Fe. Valencia 53 
F. Jiménez Díaz 40 
H. Valdecilla 25 
Centro de Análisis Genéticos. Zaragoza 22 
IGEM Valencia 20 
Laboratorio de Análisis Dr. Echevarne Barcelona 14 
H. Conxo. Santiago 21 
Clínica Universitaria Pamplona 8 
H. Central de Asturias 6 
Cryptic chromosomic alterations 
(FISH, Multitest-T and C) 
Centro Investigación Anomalías Congénitas 
Madrid. N/S 
Dementia Fronto-temporal Hospital Clínico Barcelona 30 
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Clinica Universitaria Pamplona 
Dentatorubral-pallidoluysian 
atrophy (DRPLA) 
F. Jiménez Díaz 13{-
H. La Fe. Valencia 37 
Hospital Clínico Universitario Santiago 5 
H. Central de Asturias 5 
Clínica Universitaria Pamplona 3 
Laboratorio de Análisis Dr. Echevarne Barcelona 2 
IRO Barcelona 1 
Hospital Clínico Barcelona N/S 
H. Macarena Sevilla N/S 
H. V. Rocío Sevilla N/S 
Dominant Ataxias (ADCAS) SCA1; 
SCA2 (Machado); SCA3; SCA6; 
SCA7; SCA8; SCA9; SCA10; 
SCA12 
IRO Barcelona 
F. Jiménez Díaz 
Hospital Clínico Universitario Santiago 
H. Macarena Sevilla 
Laboratorio de Análisis Dr. Echevarne Barcelona 
H. La Fe. Valencia 
H. Conxo. Santiago 
H. Central de Asturias 
Centro de Análisis Genéticos. Zaragoza 
IGEM Valencia 
Hospital Clínico Barcelona 
Clínica Universitaria Pamplona 

















Dominant macular dystrophies 
(RDS/periferina gene) 
F. Jiménez Díaz 




dystrophy H. San Pablo Barcelona 163 
H San Cecilio Granada 60 
F. Jiménez Díaz 45 
H. Universitario Las Palmas 26 
H. La Fe. Valencia 26 
Centro de Bioquímica y Genética Clínica Murcia 25 
H. La Paz. Madrid 20 
Hospital Sant Joan de Déu, Barcelona 14 
Laboratorio de Análisis Dr. Echevarne Barcelona 7 
Centro de Análisis Genéticos. Zaragoza 7 
Hospital Clínico Universitario Santiago 6 
IGEM Valencia 5 
Centro Oncológico de Galicia. A Coruna 4 
NBT DIAGEN Sevilla N/S 
H. V. Rocio Sevilla N/S 
Facioscapulohumeral muscular 
dystrophy 1A(FSHMD1A) 
H. Donostia. San Sebastián 
H. La Fe. Valencia 
IGEM Valencia 





Friedrich Ataxia (X25) F. Jiménez Díaz 135 
Hospital San Juan de Dios, Barcelona 25 
Hospital Clínico Universitario Santiago 20 
H. Valdecilla 20 
H. La Fe. Valencia 19 
IRO Barcelona 9 
Laboratorio de Análisis Dr. Echevarne Barcelona 8 
Centro de Análisis Genéticos. Zaragoza 8 
H. Central de Asturias 7 
H. Conxo. Santiago 7 
IGEM Valencia 5 
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Instituto Biología Genética Molecular. Valladolid 4 
Clínica Universitaria Pamplona 3 
H. Macarena Sevilla N/S 
Hospital Clínico Barcelona N/S 
H. Virgen de las Nieves. Granada N/S 
H. V. Rocio Sevilla NIS 
Hirschsprung disease Clínica Universitaria Pamplona 
H. Cruces Baracaldo 




Huntington disease H. Macarena Sevilla 150 
F. Jiménez Díaz 85 
H. La Fe. Valencia 65 
H Virgen del Camino 50-60 
H. La Paz. Madrid 48 
H. Central de Asturias 15 
H. Conxo. Santiago 29 
H San Cecilio Granada 25 
Hospital Clínico Universitario Santiago 25 
Laboratorio de Análisis Dr. Echevarne Barcelona 20 
H. Son Dureta Mallorca 13 
Centro de Análisis Genéticos. Zaragoza 9 
H. Miguel Servet 4 
IGEM Valencia 3 
H. Virgen de las Nieves. Granada N/S 
H. V. Rocio Sevilla N/S 
Hospital Clínico Barcelona N/S 
NBT DIAGEN Sevilla N/S 
Kaliman syndrome (microdel Xp22) F. Jiménez Diaz 
Centro de Análisis Genéticos. Zaragoza 11 
Laboratorio de Análisis Dr. Echevarne Barcelona 3 
H. V Rocio Sevilla N/S 
Kennedy disease (AR, exón 1 ) H. San Pablo Barcelona 6 
H. Macarena Sevilla 6 
Laboratorio de Análisis Dr. Echevarne Barcelona 4 
H. La Fe. Valencia 5 
H. Central de Asturias 5 
Clínica Universitaria Pamplona 3 
Instituto Biología Genética Molecular. Valladolid 1 
Centro de Análisis Genéticos. Zaragoza 1 
H. V. Rocio Sevilla N/S 
Leber optic atrophy H. Macarena Sevilla 20 
Universidad Zaragoza. Dpto Biologia Molecular 20 
IRO Barcelona 19 
Clínica Universitaria Pamplona 5 
Laboratorio de Análisis Dr. Echevarne Barcelona 5 
Centro de Análisis Genéticos. Zaragoza 3 
H. Central de Asturias 2 
H. Conxo. Santiago 2 
Lesh-Nyhan syndrome H. La Paz. Madrid 
Mental retardation FRAXE type 
linked (FMR2) H. Basurto Bilbao 
H. La Fe. Valencia 
H.Universitario Las Palmas 
H Virgen del Camino 
Hospital Clínico Universitario Santiago 
Hospital Clínico Barcelona 
H. Son Dureta Mallorca 










Myotonic distrophy of waists 
(LGMD) 
Myotonic distrophy of waists (Type 
2) (Calpainopathy, LGMD2A) 
NARP 
Neurofibromatosis type 1 
H. Son Dureta Mallorca 
H. V Rocio Sevilla 
H. San Pablo Barcelona 
H. Donostia. San Sebastián 
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Neurofibromatosis (linkage análisis H. Ramón y Cajal 
NF1 y NF2) 
IRO Barcelona 




Neuropathy due to sensitivity to 
pressure 
F. Jiménez Díaz 4 Q 
Centro de Análisis Genéticos. Zaragoza 32 
H. Valdecilla 25 
Hospital Sant Joan de Déu, Barcelona 23 
H. Conxo. Santiago 11 
H. La Fe. Valencia 9 
IGEM Valencia 5 
Laboratorio de Análisis Dr. Echevarne Barcelona 3 
Norrie disease (NPD) F. Jiménez Díaz 
Centro de Análisis Genéticos. Zaragoza 
Parkinson (Parkin, a-sinucleina) H. Donostia. San Sebastián 
Hospital Clínico Barcelona 
H. Central de Asturias 
U. Salamanca 






Prader Willi syndrome Hospital Sant Joan de Déu, Barcelona 74 
H. La Fe. Valencia 60 
H. Materno Infantil Badajoz 40 
H. Pare Tauli Barcelona 30 
H. Son Dureta Mallorca 25 
F. Jiménez Díaz 25 
Centro de Bioquímica y Genética Clínica Murcia 15 
H. Central de Asturias 13 
Η Virgen del Camino 11 
Hospital Clínico Universitario Santiago 10 
H.Universitario Las Palmas 9 
Laboratorio de Análisis Dr. Echevarne Barcelona 7 
H. Virgen de la Salud Toledo 6 
H. Miguel Servet 6 
Centro Oncológico de Galicia. A Coruna 5 
IGEM Valencia 4 
H. del Mar - UPF Barcelona 3 
Centro de Análisis Genéticos. Zaragoza 2 
Centro Investigación Anomalías Congénitas N / g 
Madrid. 
H. Virgen de las Nieves. Granada N/S 
NBT DIAGEN Sevilla N/S 




Hospital Sant Joan de Déu, Barcelona 
H. Conxo. Santiago 
H. V. Rocío Sevilla 
H. Valdecilla 
H. Son Dureta Mallorca 







Smith-Magenis syndrome H. Son Dureta Mallorca 
H. Materno Infantil Badajoz 
Hospital Clínico Universitario Santiago 
H. del Mar- UPF Barcelona 
H. Conxo. Santiago 
H. V. Rocio Sevilla 








Spinal muscular atrophy (Werdnig-
Hoffmann y Kugelberg-Welander) 
(SMN) 
H. San Pablo Barcelona 298 
H. Universitario Las Palmas 34 
H. Ramón y Cajal 127 
H. La Fe. Valencia 14 
Centro de Análisis Genéticos. Zaragoza 11 
Laboratorio de Análisis Dr. Echevarne Barcelona 8 
IGEM Valencia 4 
Instituto Biología Genética Molecular. Valladolid 2 
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H. Macarena Sevilla 
H. V. Rocio Sevilla 
N/S 
N/S 
Steinert Myotonie dystrophy H. Macarena Sevilla 300 
H. San Pablo Barcelona 263 
H. La Paz. Madrid 80 
F. Jiménez Díaz 80 
H. La Fe. Valencia 66 
H. Donostia. San Sebastián 44 
Centro de Bioquímica y Genética Clínica Murcia 35 
H Virgen del Camino Pamplona 25 
H. Cruces Baracaldo 25 
H. Miguel Servet 22 
H. Valdecilla 20 
H. Universitario Las Palmas 19 
H. Basurto Bilbao 15 
Centro de Análisis Genéticos. Zaragoza 15 
Hospital Sant Joan de Déu, Barcelona 14 
Laboratorio de Análisis Dr. Echevarne Barcelona 12 
Hospital Clínico Universitario Santiago 10 
H. Central de Asturias 6 
IGEM Valencia 4 
H. Virgen de las Nieves. Granada N/S 
NBT DIAGEN Sevilla N/S 
H. V. Rocio Sevilla N/S 
Torsion dystonia (DYT1) F. Jiménez Díaz 
Clínica Universitaria Pamplona 
H. Son Dureta Mallorca 
H. La Fe. Valencia 








Tuberose sclerosis H. Valdecilla N/S 
Willíams-Beuren syndrome (LOH 
FISH) (ATP7B) 
H. del Mar- UPF Barcelona 
Hospital Sant Joan de Déu, Barcelona 
H. La Fe. Valencia (loh) 
H. Materno Infantil Badajoz 
H. Son Dureta Mallorca 
H.Universitario Las Palmas 
Hospital Clínico Universitario Santiago 
H. Central de Asturias 
H. ParcTauli Barcelona 
F. Jiménez Díaz 
H. Virgen de la Salud Toledo 
IGEM Valencia 
H. Conxo. Santiago 
Hospital Clínico Barcelona 
Centro Investigación Anomalías Congénitas 
Madrid. 


















H. Virgen de las Nieves. Granada 
H. V. Rocio Sevilla 






Hospital Sant Joan de Déu, Barcelona 308 
H. La Fe. Valencia 295 
H. Basurto Bilbao 268 
Centra de Bioquímica y Genética Clínica Murcia 250 
H. Macarena Sevilla 225 
H. Ramón y Cajal 195 
H. Son Dureta Mallorca 170 
H. Miguel Servet 129 
F. Jiménez Díaz 110 
H.Universitario Las Palmas 93 
H San Cecilio Granada 90 
Centro Oncológico de Galicia. A Coruna 80 
Centro de Análisis Genéticos. Zaragoza 73 
H. Virgen de la Salud Toledo 63 
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H Virgen del Camino 60 
Instituto Biología Genética Molecular. Valladolid 53 
IGEM Valencia 50 
Laboratorio de Análisis Dr. Echevarne Barcelona 39 
Hospital Clínico Universitario Santiago 35 
H. Central de Asturias 17 
H. del Mar-UPF Barcelona 10 
Hospital Clínico Barcelona N/S 
ANCOR Alicante N/S 
H. Virgen de las Nieves. Granada N/S 
H. V. Rocio Sevilla N/S 
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HEMATOLOGIC CONDITIONS 
Centre N. tests 2001 
ACE Angiotensin I convertor 
enzyme 
NBT DIAGEN Sevilla N/S 
Bruton type inmuno-deficiency H. La Fe. Valencia 14 
Chimerism determination for 
bone marrow transplants H. Carlos Haya 
H. Son Dureta Mallorca 
Centra Oncológico de Galicia. A Coruna 
H. Virgen de las Nieves. Granada 
Leukemia 
Thrombophilia (Mut. G1691A 
factor V Leiden gene) (Mut 
G20210A protrombina gene) 
Hospital Juan Canalejo 
H. Conxo. Santiago 
Laboratorio de Análisis Dr. Echevarne Barcelona 
H Virgen del Camino Pamplona 
Centro de Análisis Genéticos. Zaragoza 
H. Carlos Haya 
H. Central de Asturias. 






Factor II G20210A 
Haemophilia A 
Haemophilia B 
H. San Pablo Barcelona 
NBT DIAGEN Sevilla 
H. San Pablo Barcelona 
Laboratorio de Análisis Dr. Echevarne Barcelona 
IGEM Valencia 
ANCOR Alicante 
H. San Pablo Barcelona 











H. del Mar - UPF Barcelona 800 
H. Conxo. Santiago 168 
H. Carlos Haya ' 147 
CNIO Madrid 100 
H Virgen del Camino 50 
Laboratorio de Análisis Dr. Echevarne Barcelona 16 
ANCOR Alicante N/S 
H. Virgen de las Nieves. Granada N/S 
Leukemia and limphoma 




Mut C>T 677 MTHFR gene 
Other oncohematologic 
conditions 
PAI-I Plasminogen activator 
inhibitor 




H. Virgen de la Salud Toledo 
NBT DIAGEN Sevilla 
Centro Oncológico de Galicia. A Coruna 
H Virgen del Camino Pamplona 
H. Gregorio Marañón 
NBT DIAGEN Sevilla 
H Virgen del Camino Pamplona 
H. Conxo. Santiago 
CNIO Madrid 
NBT DIAGEN Sevilla 
H. La Paz. Madrid 
H. San Pablo Barcelona 
Centro de Análisis Genéticos. Zaragoza 
Laboratorio de Análisis Dr. Echevarne Barcelona 
H. Virgen de las Nieves. Granada 
H. San Pablo Barcelona 
Centro de Análisis Genéticos. Zaragoza 
Laboratorio de Análisis Dr. Echevarne Barcelona 
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IRO Barcelona 
U. Salamanca 
F. Jiménez Díaz 
H. Valdecilla 
ANCOR Alicante 
H. Gregorio Marañón 








Thrombophilia (Mut C677T) H. Valdecilla 
Thrombophilia H. Valdecilla 
(metilentetrahidrofolatoreductas 
a) 





Centre N.tests 2001 
Adenomatous polyposis of the colon 
(APC) 
Clinica Universitaria Pamplona 36 
H Virgen del Camino Pamplona 28 
H. La Fe. Valencia 20 
H. Conxo. Santiago 19 
CNIO Madrid 10 
Laboratorio de Análisis Dr. Echevarne Barcelona 7 
H. Valdecilla 5 
Centro de Análisis Genéticos. Zaragoza 1 
H. San Carlos Madrid N/S 
Hospital Clínico Barcelona N/S 
H. Virgen de las Nieves. Granada N/S 
NBT DIAGEN Sevilla N/S 
H. V. Rocio Sevilla N/S 
Adenomatous polyposis of the colon 
(Gen P53, Gen kRAS, Gen hMHS2, Gen 
hMLH1, Gen hPMS1,Gen hPMS2) 





Beta tubulina H. Miguel Servet 10 
Bladder sporadic cancer U. Valencia 40 
Breast cancer (BCRA1 y BCRA2) H. San Pablo Barcelona 79 
H. San Carlos Madrid 50 
U. Salamanca 50 
Clínica Universitaria Pamplona 50 
CNIO Madrid 45 
H. del Mar - UPF Barcelona 20 
H. Conxo. Santiago 13 
Laboratorio de Análisis Dr. Echevarne Barcelona 2 
Centra de Análisis Genéticos. Zaragoza 2 
Hospital Clínico Barcelona N/S 
H. V. Rocio Sevilla N/S 
ANCOR Alicante N/S 




Familiar feochromocitome CNIO Madrid 
H. Cruces Baracaldo 
Clínica Universitaria Pamplona 
Centro de Análisis Genéticos. Zaragoza 
H. La Fe. Valencia 
NBT DIAGEN Sevilla 








Familiar medullar thyroid cancer FMTC 
Familiar melanoma (pl5, p19,CDK4) 
Familiar melanoma (pl6) 
H. V. Rocio Sevilla 
Hospital Clínico Barcelona 
Clínica Universitaria Pamplona 
Hospital Clínico Barcelona 
Centro de Análisis Genéticos. Zaragoza 
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CNIO Madrid 
GST mu (colon, bladder) U. Salamanca 
Clinica Universitaria Pamplona 
400 
59 
HLXB9 CNIO Madrid 
HNPCC markers for MSI Panel 5 micro 
satellites instability 
ANCOR Alicante N/S 
K-RAS (CODON 12, 13) (lung, colon, 
ovary, larynx) 
Clinica Universitaria Pamplona 







Kidney sporadic cancer U. Valencia 60 
Li-Fraumeni disease (p53) U. Salamanca 10 
Clinica Universitaria Pamplona 9 
H. San Pablo Barcelona 8 
Laboratorio de Análisis Dr. Echevarne Barcelona 3 
Η. Conxo. Santiago 2 
Centro de Análisis Genéticos. Zaragoza 2 
H. San Carlos Madrid N/S 
ANCOR Alicante N/S 
Centro Oncológico de Galicia. A Coruna N/S 
NBT DIAGEN Sevilla N/S 
H. V. Roclo Sevilla N/S 
Lynch Syndrome 
Meningions sporadic cancer 
Centro de Bioquímica y Genética Clínica Murcia 
H. V. Rocio Sevilla 
NBT DIAGEN Sevilla 







Multiple Endocrine Neoplasia type 1 
(MENI) 
H. Cruces Baracaldo 40 
Centro de Bioquímica y Genética Clínica Murcia 25 
CNIO Madrid 20 
Hospital Clínico Barcelona N/S 
Clínica Universitaria Pamplona 7_ 
Multiple Endocrine Neoplasia, type IIA 
(MEN2A) 
CNIO Madrid 40 
Centra de Bioquímica y Genética Clínica Murcia 25 
Clínica Universitaria Pamplona 19 
H. La Fe. Valencia 16 
H. Cruces Baracaldo 5 
H. Conxo. Santiago 4 
Centro de Análisis Genéticos. Zaragoza 2 
H. Virgen de las Nieves. Granada N/S 
NBT DIAGEN Sevilla N/S 
H. V. Rocio Sevilla N/S 
Multiple Endocrine Neoplasia type II Β 
(MEN2B) 
H. Cruces Baracaldo 
Centro de Análisis Genéticos. 
H. La Fe. Valencia. 
H. Conxo. Santiago 
NBT DIAGEN Sevilla 






Neuroblastomes sporadic cancer U. Valencia 70 
Non polyposic colonie cancer CNIO Madrid 
Hospital Clínico Barcelona 
15 
N/S 
p53 EXONES 4,5,6,7,8 (Lung, breast, 
ovary, Endomet.) 
Clínica Universitaria Pamplona „ f i q 
U. Salamanca 200 
H.San Carlos 130 
H. Miguel Servet 105 
H. Cruces Baracaldo 50 
U. Valencia 50 
H. Conxo. Santiago 47 
CNIO Madrid 10 
Laboratorio de Análisis Dr. Echevarne Barcelona 5 
Centro de Análisis Genéticos. Zaragoza 2 
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Von Hippel Lindau disease 
ANCOR Alicante 
H. V. Rocio Sevilla 
H. Macarena Sevilla 
CNIO Madrid 
Clínica Universitaria Pamplona 
H. La Fe. Valencia 
U. Salamanca 
Centro de Análisis Genéticos. Zaragoza 
H. Conxo. Santiago 
Hospital Clínico Barcelona 




PSA (prostate cancer) 
PTEN 
Retinoblastoma 
Sarcomes sporadic cancer 
Thyroid medullar sporadic cancer 
Tirosinasa (tyroid cancer) 
Tirosinasa (melanoma) 
Clinica Universitaria Pamplona 
CNIO Madrid 
H. La Fe. Valencia 
Centro de Análisis Genéticos. Zaragoza 
U. Valencia 
H. Cruces Baracaldo 
H. V. Rocio Sevilla 
H. Conxo. Santiago 
























H. Conxo. Santiago 
5 a-reductasa tipo 2 deficiency H. Valle Hebron Barcelona 
11-beta-hidroxilasa deficiency H. Gregorio Marañón 
H. Conxo. Santiago 




17-alpha-hydroxylase deficiency H. Conxo. Santiago 





H. de Cruces Baracaldo 
H. Valle Hebron 
21-hydroxylase deficiency H. Gregorio Marañón Madrid 400 
H. La Paz. Madrid 352 
H. Conxo. Santiago 60 
Hospital Sant Joan de Déu, Barcelona 51 
Laboratorio de Análisis Dr. Echevarne Barcelona 3 
H. San Millán. Logroño N/S 
Adrenal hyperplasia congenital 
Adrenal hypoplasia congenital 
Alfa-1-antitripsina deficiency 
Apolipoprotein Β (APOB) deficiency 
Camitina palmitoil transferasa II 
deficiency (Y628S mutation) 
Carnitina palmitoil transferasa II 
deficiency (S113L mutation) 
Cerebrotendinosis Xantomatosa 
(CYP27) 
Maturity-onset diabetes ofthe 
H. La Paz. Madrid 
H. Conxo. Santiago 
Hospital Clínico Barcelona 
H. Central de Asturias. 
Η. Conxo. Santiago 
Η. La Paz. Madrid 
Η. Macarena Sevilla 
NBT DIAGEN Sevilla 
H. San Millán. Logroño 
Universidad Zaragoza. Dpto Biología Molecular 
H. Conxo. Santiago 
NBT DIAGEN Sevilla 
H. 12 de Octubre 
H. 12 de Octubre 
Centro de Diagnóstico de Enfermedades 
Moleculares Madrid 
H. Conxo. Santiago 
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young MODYtype (GK, HNF1) 
Diabetes type I (HLA susceptibility) 
Gaucher disease 
H. de Cruces Baracaldo 
Hospital Clinico Barcelona 
H. La Paz. Madrid 
Universidad Zaragoza. Dpto Biologia Molecular 





Growth hormone deficiency H. Valle Hebron Barcelona 
H. Conxo. Santiago 
H. La Paz. Madrid 
Hospital Clinico Barcelona 
Medium Chain Acil-CoA 
deshidrogenasa deficiency (MCAD) 
(K304E mutation) 
Laboratorio de Análisis Dr. Echevarne Barcelona 
Instituto Biología Genética Molecular. Valladolid 
Hospital Clínico Barcelona 
H. Conxo. Santiago 
H. Universitario Las Palmas 
Centro de Diagnòstico de Enfermedades 
Moleculares Madrid 
H. Gregorio Marañón 
Hospital Clínico Barcelona 


















Hyperlipoproteinemia type III, 
disbetalipoproteinemia 
McArdle disease (miofosforilasa 
deficiency) Mutations R49X, G204S 
y W797R 
H. San Millán. Logroño 
H. Conxo. Santiago 
H. La Paz. Madrid 
Laboratorio de Análisis Dr. Echevarne Barcelona 
Hospital Clínico Barcelona 
H. La Fe. Valencia 
Hospital Clínico Barcelona 
Universidad Zaragoza. Dpto Biologia Molecular 
H. Conxo. Santiago 
Universidad Zaragoza. Dpto Biología Molecular 












Methyl crotonil glicinuria (MCCA 
and MCCB Genes) 
Methylenetetrahydrofolate-5,10 
reductase (MTHFR) 677C—T 
MTRR 66 G->A 
Mioadenilato desaminasa 
deficiency, Q12X mutation 
Mucolipidosis III 






Propionic acidemia (PCCA and 
PCCB Genes) 
Smitz-Lemli-Opitz syndrome 7-
Esterol Reductasa (DRCR7) 
Triple A syndrome 
Centra de Diagnóstico de Enfermedades 
Moleculares Madrid 
Centro de Diagnóstico de Enfermedades 
Moleculares Madrid 
Centro de Diagnóstico de Enfermedades 
Moleculares Madrid 
H. 12 de Octubre 
Centro de Análisis Genéticos. Zaragoza 
H. Conxo. Santiago 
Centro de Diagnóstico de Enfermedades 
Moleculares Madrid 
H. Conxo. Santiago 
H. Universitario Tenerife 
H. San Millán. Logroño 
H. Universitario Tenerife 
Centro de Diagnóstico de Enfermedades 
Moleculares Madrid 
Centro de Diagnóstico de Enfermedades 
Moleculares Madrid 
Centro de Análisis Genéticos. Zaragoza 
Hospital Clínico Barcelona 
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PRIMARY IMMUNODEFICIENCIES 
Autosomic agammaglobulinemia (μ 
chain) 
Agammaglobulinemia X linked 
Apoptosis deficiency ( APO 1 ) 
Β. Cesar-Chediak-Higashi disease 
Combined deficiency X linked (yR-IL2 
chain) 
Complement deficiencies 
Di George syndrome 
Η LA type II molecules deficiency 
Hyper IgM syndrome 
Leukocyte adhesion deficiency, type I 
and II 
Omenn syndrome, RAG 1, RAG 2 
Combined autosomic recesive 
deficiency 
Screening for poligenetic disorders 
Wisckott-Aldrich syndrome 
Centre 
H. La Paz. Madrid 
H. La Paz. Madrid 
H. La Paz. Madrid 
H. Valdecilla 




H. La Paz. Madrid 
H. Valdecilla 




















Absence of deferent conduct 
Centre 






H. Gregorio Marañón Madrid _.. 
H. La Paz. Madrid 44 
F. Jiménez Díaz 20 
H. Son Dureta Mallorca 5 
H. Conxo. Santiago 3 
H. Central de Asturias. 3 
Centro de Bioquímica y Genética Clínica Murcia 2 
H.Universitario Las Palmas 2 
Centro de Análisis Genéticos. Zaragoza 2 
Hospital Clínico Barcelona N/S 
H. Miguel Servet 2 
Alport syndrome H. Conxo. Santiago 
AIDS (D32-CCR5, V64I-CCR2, SDF1-
3Ά, RANTES-403C>A, RANTES-
280G) 
H. V. Rocio Sevilla N/S 
Aneuploidies Centro Oncológico de Galicia. A Coruna 80 
Azoospermia and oligospermia 
(Microdelection er. Y) 
Hospital Clínico Barcelona 
290 
H. Virgen de la Salud Toledo 86 
Centro de Patología Celular. Barcelona 61 
H. Son Dureta Mallorca 50 
H. Macarena Sevilla 50 
F. Jiménez Díaz 40 
Laboratorio de Análisis Dr. „ q 
Echevarne Barcelona 
H. Miguel Servet 36 
U. Salamanca 25 
H. Universitario Tenerife 24 
H. Central de Asturias. 21 
Centro de Bioquímica y Genética Clínica Murcia 10 
Centro de Análisis Genéticos. Zaragoza 13 
Centro Oncológico de Galicia. A Coruna 10 
H Virgen del Camino 8 
Hospital Clínico Universitario Santiago 3 
NBT DIAGEN Sevilla N/S 
Beckwith-Wiedemann syndrome H. La Fe. Valencia 
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Cavernomatosis H. Macarena Sevilla 140 
Celiac disease H Virgen del Camino Pamplona 
Instituto Biología Genética Molecular. Valladolid 










H. San Millán. Logroño 
Policlínica Gipuzkoa. San Sebastián 
IRO Barcelona 






IRO Barcelona 574 
Instituto Biología Genética Molecular. Valladolid 200 
H. Macarena Sevilla 180 
H. La Fe. Valencia 179 
H. Son Dureta Mallorca 110 
H. La Paz. Madrid 93 
Centro Oncológico de Galicia. A Coruna 60 
H. Ramón y Cajal 53 
Centro de Bioquímica y Genética Clínica Murcia 50 
F. Jiménez Díaz 50 
Centro de Patología Celular. Barcelona 44 
H.Universitario Las Palmas 43 
H Virgen del Camino 43 
Centro de Análisis Genéticos. Zaragoza 36 
H. Cruces Baracaldo 32 
Hospital Sant Joan de Déu, Barcelona 31 
H San Cecilio Granada 30 
Hospital Clínico Universitario Santiago 23 
H. Miguel Servet 19 
H. Universitario Tenerife 18 
Laboratorio de Análisis Dr. . „ 
Echevarne Barcelona 
H. Central de Asturias. 9 
H. Conxo. Santiago 5 
IGEM Valencia 5 
H. Gregorio Marañón Madrid N/S 
H. Virgen de las Nieves. Granada N/S 
Hospital Clínico Barcelona N/S 
NBT DIAGEN Sevilla N/S 
H. V. Rocío Sevilla N/S 
Deafness, linked to Conexina 26 gene H. Ramón y Cajal 
Clinica Universitaria Pamplona 
H.Universitario Las Palmas 
F. Jiménez Díaz 
Centro de Análisis Genéticos. Zaragoza 
H. V. Rocio Sevilla 







Deafness, linked to Conexina 32 gene Centra de Análisis Genéticos. Zaragoza 
600 
Deafness, neurosensorial, linked to 
mitochondrial DNA, A1555G mutation 
H. 12 de Octubre 36 
Deafness, mitochondrial (by ototoxics) F. Jiménez Díaz 
Deafness sporadic (otoferlina gene) H. Ramón y Cajal 300 
Di George syndrome H. La Fe. Valencia 
Hospital Clínico Universitario Santiago 
H. Son Dureta Mallorca 
Centro Oncológico de Galicia. A Coruna 
H. Miguel Servet 
H Virgen del Camino 
Centro de Patología Celular. Barcelona 
IGEM Valencia 
H. Conxo. Santiago 
H. V. Rocio Sevilla 












Di George syndrome / S. 
Velocardiofacial syndrome (FISH) 
H. Parc Taulí 32 
Emery-Dreifuss disease H. La Fe. Valencia 
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Epidermolysis bullosa H. La Fe. Valencia 1 
Espondiloartropaties (b27 genotyping) Policlínica Gipuzkoa. San Sebastián N/S 
Factor V Deficiency H. Miguel Servet 
H. Cruces Baracaldo 
Centro de Análisis Genéticos. Zaragoza 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
H. Central de Asturias. 
H. Carlos Haya 
IRO Barcelona 
U. Salamanca 
H. Conxo. Santiago 
F. Jiménez Díaz 
H. Universitario Tenerife 
ANCOR Alicante 
H. Gregorio Marañón Madrid 
H. Virgen de las Nieves. Granada 
NBT DIAGEN Sevilla 
H. V. Rocio Sevilla 


















U. Alicante N/S 
Gilbert syndrome H. San Pablo Barcelona 
Hemocrhomatosís (HFE) 
190 
H. Cruces Baracaldo 968 
H. Miguel Servet 410 
H. San Pablo Barcelona 385 
H. La Fe. Valencia 314 
Hospital Clínico Barcelona 300 
Centro de Análisis Genéticos. Zaragoza 312 
Laboratorio de Análisis Dr. „ y 
Echevarne Barcelona 
F. Jiménez Díaz 207 
H. Macarena Sevilla 200 
H. Conxo. Santiago 187 
H Virgen del Camino 162 
H. La Paz. Madrid 162 
H. San Millán. Logroño 110 
U.Valencia 100 
U. Salamanca 75 
H. Universitario Tenerife 64 
H San Cecilio Granada 60 
Instituto Biología Genética Molecular. Valladolid 60 
Centro Oncológico de Galicia. A Coruna 30 
H. Son Dureta Mallorca 20 
Hospital Clínico Universitario Santiago 10 
IGEM Valencia 5 
H. V. Rocio Sevilla N/S 
H. Virgen de las Nieves. Granada N/S 
NBT DIAGEN Sevilla N/S 
ANCOR Alicante N/S 
Hemochromatosis (MUTACIONES 
C282Y, H63D, S65C) 
Policlínica Gipuzkoa. San Sebastián 15 
Holoprosencefalia H. Conxo. Santiago 
Homocystinuria MTHFR H. Miguel Servet 
Hospital Sant Joan de Déu, Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
IRO Barcelona 
H. Conxo. Santiago 







HPV Laboratorio de Análisis Dr. Echevarne Barcelona 295 
Incontinentia pigmenti H. La Fe. Valencia N/S 
Mediterranean familiar fever F. Jiménez Díaz 
H. Valdecilla 
Hospital Clínico Universitario Santiago 
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Mental retardation familiar ¡nespecific 
Miller-Diecker syndrome 
H. V. Rocio Sevilla 
H. La Fe. Valencia 




Morris syndrome, Reifenstein 
syndrome (AR exons 2-8) 
H. Valle Hebron 
H. Cruces Baracaldo 
Clínica Universitaria Pamplona 
H. Conxo. Santiago 
Hospital Clínico Barcelona 
Polycystic Kidney Disease I (PKD1) H. Conxo. Santiago 
H. Ramón y Cajal 
H. Central de Asturias. 
Centro de Análisis Genéticos. Zaragoza 
Hospital Clínico Barcelona 






Narcolepsy (H LA markers) 
Nephronophthisis, familial juvenile 
1(NPHP1) 
Non Hodgking lynphomes: bcl2/lgH y 
Bcl1/lgH 





Policlínica Gipuzkoa. San Sebastián 
H. Central de Asturias. 
H. Universitario Tenerife 
Hospital Clínico Barcelona 
H. Carlos Haya 
F. Jiménez Díaz 
Centro de Análisis Genéticos. Zaragoza 
Hospital Clínico Barcelona 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Cruces Baracaldo 



















Polycystic Kidney Disease 2 (PKD2) H. Central de Asturias. 
H. Conxo. Santiago 
H. Son Dureta Mallorca 





Porphyria Acute intermittent (AIP) H. La Paz. Madrid 29 
Porphyria, congenital erythropoietic H. La Paz. Madrid N/S 
Protrombine gene H. Miguel Servet 
H. Cruces Baracaldo 
Centro de Análisis Genéticos. Zaragoza 
H. Conxo. Santiago 
H. Central de Asturias. 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
H. Carlos Haya 
IRO Barcelona 
U. Salamanca 
F. Jiménez Díaz 
Η. Universitario Tenerife 
Η. Gregorio Marañón Madrid 
H. Virgen de las Nieves. Granada 

















Retinitis pigmentosa autosomic 
dominant (genes RHO y RDS) 
Retinitis pigmentosa X linked 
Retinitis pigmentosa, autosomal 
recessive 
Retinoschisis, X-linked juvenile (RS1) 
H. Cruces Baracaldo 
H. Conxo. Santiago 
F. Jiménez Díaz 
H. V. Rocío Sevilla 
F. Jiménez Díaz 
H. V. Rocío Sevilla 
F. Jiménez Díaz 
H. San Pablo Barcelona 
H. V Rocio Sevilla 
H. San Pablo Barcelona 
H. V. Rocio Sevilla 
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Rheumathoid artritis (HLA markers) 
Rickets D-vit resistant VDR gene 
Russel Silver syndrome 
Sex determination 
SHOX gene linked conditions 
H. La Fe. Valencia 
Policlínica Gipuzkoa. San Sebastián 
H. Valle Hebron 
H. del Mar - UPF Barcelona 
Hospital Sant Joan de Déu, Barcelona 







SRY Gene (sexual development 
alterations) 
H. Miguel Servet. Zaragoza 
H. La Paz. Madrid 
H. Central de Asturias. 
F. Jiménez Díaz 
H Virgen del Camino 
Hospital Clínico Barcelona 
H. Cruces Baracaldo 
H. Gregorio Marañón Madrid 
Centro Oncológico de Galicia. A Coruna 
Centro de Patología Celular. Barcelona 
U. Salamanca 
H. V. Rocío Sevilla 













SRY gene / Amilogenina gene 
Uniparental disomy 14 
Uniparental disomy 15 
Uniparental disomy 7 
Usher syndrome 
WAGR syndrome 
H. V. Rocio Sevilla 
Centra de Análisis Genéticos. 
H. La Fe. Valencia 
Hospital Clínico Barcelona 
Centro de Análisis Genéticos. 
Centro de Análisis Genéticos. 
H. La Fe. Valencia 












Hospital Clínico Barcelona 20 
Clínica Universitaria Pamplona 12 
Instituto Biología Genética Molecular. Valladolid 8 
Centro Oncológico de Galicia. A Coruna N/S 
H. La Paz. Madrid N/S 





Mitochondrial disorders : Leigh, MERRF, 
MELAS, Pearson, Kerans-Sayre, 
depleciones, etc 
Mitochondrial myopathy, 
encephalopathy, lactic acidosis and 
strokelike episodes (MELAS) 
H. 12 de Octubre 
Universidad Zaragoza. Dpto Biología Molecular 
Hospital Valle Hebron. Barcelona 






MELAS y MERRF 
Hospital Clínico Barcelona 
Centro de Análisis Genéticos. Zaragoza 











Laboratorio de Análisis Dr. Echevarne Barcelona 
Laboratorio de Análisis Dr. Echevarne Barcelona 
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Annex 6. Hereditary diseases tested and centres classified by 
autonomous regions 
ANDALUCÍA 
Population: 7.403.968 inhabitants. 
There are five public hospitals which perform genetic tests and one private laboratory 
that ave started activity very recently. 
The number of hereditary diseases that can be tested in those centres is 64. 
NEUROLOGIC CONDITIONS Centres 
N. test 2001 
(N/S when not 
specified) 
Alzheimer disease (Presenilina 1, APP, 
APOE) 
H. Macarena Sevilla 
NBT DIAGEN Sevilla 
20 
N/S 
Angelman syndrome H. V. Rocio Sevilla 




(DRPLA) H. Macarena Sevilla 
H. V. Rocio Sevilla 
N/S 
N/S 
Dominant Ataxias (ADCAS) SCA1 ; 
SCA2 (Machado) 
SCA3; SCA6; SCA7; SCA8; SCA9;SCA10; 
SCA12 
H. Macarena Sevilla 
Huntington disease H. Macarena Sevilla 
H. San Cecilio Granada 
H. V. Rocio Sevilla 
H. Virgen de las Nieves. Granada 
NBT DIAGEN Sevilla 
N/S (250 among 
all ataxias) 
Dominant macular dystrophies 
(RDS/periferina gene) 
Duchenne - Becker muscular dystrophy 
Facioscapulohumeral muscular 
1A(FSHMD1A) 




H. V. Rocio Sevilla 
H. V. Rocio Sevilla 
H. San Cecilio Granada 
H. V. Rocio Sevilla 
NBT DIAGEN Sevilla 
H. V. Rocío Sevilla 
H. Macarena Sevilla 
H. San Cecilio Granada 
H. V. Rocio Sevilla 
H. Virgen de las Nieves. 
H. Macarena Sevilla 
H. V. Rocio Sevilla 
H. Virgen de las Nieves. 























Kennedy disease (AR, exon 1) 
Leber optic atrophy 
Miller-Dieker syndrome 
Myotonic dystrophy Steinert 
Prader Willi syndrome 
Rett syndrome 
Smith-Magenis syndrome 
H. V. Rocio Sevilla 
H. Macarena Sevilla 
H. V. Rocio Sevilla 
H. Macarena Sevilla 
H. V. Rocio Sevilla 
H. Macarena Sevilla 
H. V. Rocio Sevilla 
H. Virgen de las Nieves. Granada 
NBT DIAGEN Sevilla 
H. V. Rocio Sevilla 
H. Virgen de las Nieves. Granada 
NBT DIAGEN Sevilla 
H. V. Rocio Sevilla 
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Spinal muscular atrophy (Werdnig-
Hoffmann y Kugelberg-Welander) (SMN) 
Williams-Beuren syndrome (LOH , FISH) 
(ATP7B) 
Wolf-Hirshhorm syndrome 
H. Macarena Sevilla 
Η. V. Rocío Sevilla 
Η. V. Rocio Sevilla 
Η. Virgen de las Nieves. Granada 







ACE Angiotensin 1 converter enzyme 
Alpha thalassemia 
Beta thalassemia 
Factor II G20210A 
Leukemias 
Lymphomas 
Metilen TetraHidrofolato Reductasa 
(MTHFR) 
PAI-I Plasminogen activator inhibitor 
Thrombophilia (Mut. G1691A factor V) 
(Mut G20210A protrombina) 
NBT DIAGEN Sevilla 
Η. Virgen de las Nieves. Granada 
Η. Virgen de las Nieves. Granada 
NBT DIAGEN Sevilla 
H. Carlos Haya 
H. Virgen de las Nieves. Granada 
NBT DIAGEN Sevilla 
NBT DIAGEN Sevilla 
NBT DIAGEN Sevilla 
NBT DIAGEN Sevilla 
H. V. Rocio Sevilla 
















Apolipoprotein Β (APOB) deficiency 
H. Macarena Sevilla 
H. V. Rocío Sevilla 
NBT DIAGEN Sevilla 






Adenomatous polyposis of the colon (APC) 
Breast cancer (BCRA1 y BCRA2) 
Familiar medullar thyroid cancer FMTC 
Familiar feochromocitome 
Li-Fraumeni disease (p53) 
Lynch syndrome 
Multiple endocrine neoplasia, type MA 
(MEN2A) 
Multiple Endocrine Neoplasia type II Β 
(MEN2B) 
p53 EXONES 4,5,6,7,8 (Lung, breast, 
ovary, endometrio) 
Thyroid sporadic cancer 
Von Hippel Lindau disease 
H. V. Rocío Sevilla 
H. Virgen de las Nieves. Granada 
NBT DIAGEN Sevilla 
H. V. Rocio Sevilla 
H. V. Rocio Sevilla 
H. V. Rocio Sevilla 
NBT DIAGEN Sevilla 
H. V. Rocio Sevilla 
NBT DIAGEN Sevilla 
H. V. Rocio Sevilla 
H. Virgen de las Nieves. Granada 
NBT DIAGEN Sevilla 
H. V. Rocio Sevilla 
H. Virgen de las Nieves. Granada 
NBT DIAGEN Sevilla 
H. V. Rocio Sevilla 
NBT DIAGEN Sevilla 
H. V. Rocio Sevilla 
H. Macarena Sevilla 
H. V. Rocio Sevilla 























Absence of deferent conduct 
AIDS (D32-CCR5, V64I-CCR2, SDF1-3'A, 
RANTES-403OA, RANTES-280G) 
Azoospermia and oligospermia 
Cavernomatosis 
Chimerism determination for bone marrow 
transplant 
Cystic fibrosis 
NBT DIAGEN Sevilla 
H. V. Rocio Sevilla 
H. Macarena Sevilla 
NBT DIAGEN Sevilla 
H. Macarena Sevilla 
H. Carlos Haya 
H. Macarena Sevilla 
H. San Cecilio Granada 
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H. V. Rocio Sevilla 
NBT DIAGEN Sevilla 
N/S 
N/S 
68 -xxiiiDeafness, linked to 
Conexina 26 gene 
H. V. Rocio Sevilla N/S 
Di George syndrome H. V. Rocio Sevilla N/S 
Factor V Deficiency H. Carlos Haya 
H. V. Rocio Sevilla 
H. Virgen de las Nieves. Granada 





Hemochromatosis (HFE) H. Macarena Sevilla 
H. San Cecilio Granada 
H. Virgen de las Nieves. Granada 
H. V. Rocío Sevilla 







Mediterranean familiar fever 
Non Hodgking lynphomes: bcl2/lgH y 
BcM/lgH 




Retinitis pigmentosa autosomic dominant 
(genes RHO y RDS) 
Retinitis pigmentosa, autosomal recessive 
Retinoschisis, X-linked juvenile (RS1) 
SRY gene 
H. Virgen de las Nieves. Granada 
H. V. Rocio Sevilla 
H. Carlos Haya 
H. Virgen de las Nieves. Granada 
H. Carlos Haya 
H. V. Rocio Sevilla 
H. Virgen de las Nieves. Granada 
H. V. Rocío Sevilla 
H. V. Rocio Sevilla 
H. V. Rocio Sevilla 
H. V. Rocio Sevilla 
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ARAGON 
Population: 1.199.753 inhabitants. 
There are 3 centres in which genetic tests are performed, of them 2 are public centres 
(1 hospital and 1 university centre) and 1 private centre. 
The number of conditions that can be tested in those centres is 55. 
NEUROLOGIC CONDITIONS 





Dominant ataxias (ADCAS) SCA1 ; 
SCA2 (Machado) SCA3; SCA6; SCA7; 
SCA8; SCA9; SCA10; SCA12 
Duchenne - Becker muscular 
dystrophy 
Fragile-X syndrome 
Friedrich Ataxia (X25) 
Huntington disease 
Kennedy disease. (AR, exón 1) 
Leber optic atrophy 
MELAS 
Myotonic dystrophy Steinert 
Neurofibromatosis type 1 
Neurophathy due to pressure 
sensitivity 
Norrie disease 
Prader Willi syndrome 
Spinal muscular atrophy (Werdnig-
Hoffmann y Kugelberg-Welander) 
(SMN) 
Torsion dystonia (DYT1) 
Centres 
H. Miguel Servet 
Centro de Análisis Genéticos. Zaragoza 
H. Miguel Servet 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
H. Miguel Servet 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
H. Miguel Servet 
Centro de Análisis Genéticos. Zaragoza 
Universidad Zaragoza. Dpto Biología Molecular 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
H. Miguel Servet 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
H. Miguel Servet 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 































Thrombophilia (Mut G1691A factor V) 
(Mut G20210A protrombina) 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 





Apolipoprotein Β (APOB) deficiency 
Gaucher disease 
Hypercholesterolemia 
Hyperliproteinemia type III, 
disbetalipoproteinemia ( 
Hyperlipoproteinemia type III) 
Mucolipidosis III 
Smitz-Lemli-Opitz síndrome 7- Esteral 
Reductasa (DRCR7) 
Universidad Zaragoza. Dpto Biologia Molecular 
Universidad Zaragoza. Dpto Biologia Molecular 
Universidad Zaragoza. Dpto Biologia Molecular 
Universidad Zaragoza. Dpto Biologia Molecular 
Centro de Análisis Genéticos. Zaragoza 
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NEOPLASIC CONDITIONS 
Adenomatous polyposis of the colon 
(APC) 
Beta tubulina 
Breast cancer (BCRA1 y BCRA2) 
Familiar feochromocitome 
Familiar melanoma (pl5, p19,CDK4) 
Li-Fraumeni disease (p53) 
Multiple Endocrine Neoplasia 
MEN2A 
Multiple Endocrine Neoplasia 
MEN2B 
p53 EXONES 4,5,6,7,8 (Lung, 
breast, ovary, endometrio) 
Retinoblastoma 
Von Hippel Lindau disease 
Centro de Análisis Genéticos. Zaragoza 
H. Miguel Servet 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
H. Miguel Servet 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 














Mitochondrial disorders: Leigh, 
MERRF, MELAS, Pearson, Kerans-
Sayre, etc 







Deafness, linked to Conexina 26 
gene 
Deafness, rRNA 12S mitochondrial 
gene (Conexina 26) 
Di George syndrome 
Factor V deficiency 
Hemochromatosis 
Mediterranean familiar fever 
MTHFR 
Norrie disease(NDP) 
Polycystic Kidney Disease 1 
Protrombine gene 
SRY gene 
SRY gene / gen Amilogenina 
Uniparental disomy 7 
Uniparental disomy 15 
Centro de Análisis Genéticos. Zaragoza 
H. Miguel Servet 
H. Miguel Servet 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
H. Miguel Servet 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
H. Miguel Servet 
H. Miguel Servet 
Centro de Análisis Genéticos. Zaragoza 
H. Miguel Servet 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
H. Miguel Servet 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
H. Miguel Servet 
Centro de Análisis Genéticos. Zaragoza 
H. Miguel Servet 
Centro de Análisis Genéticos. Zaragoza 
Centro de Análisis Genéticos. Zaragoza 
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ASTURIAS 
Population: 1.075.329 inhabitants. 
There is only 1 centre, a public hospital, in which genetic tests are performed 
The number of conditions that can be tested in this centre is 25. 
NEUROLOGIC CONDITIONS 
Alzheimer disease(Presenilina 1, APP, APOE) 
Angelman syndrome 
Charcot-Marie-Tooth neuropathy 
Dentatorubral-pallidoluysian atrophy (DRPLA) 
Dominant ataxias (ADCAS) SCA1 





Kennedy disease. (AR, exón 1) 
Leber optic atrophy 
Myotonic dystrophy Steinert 
Parkinson (Parkin, a-sinucleina) 
Prader Willi syndrome 
Williams-Beuren syndrome (LOH 
SCA2 
; SCA8; SCA9; 
FISH) (ATP7B) 
Centres 
H. Central de Asturias 
H. Central de Asturias 
H. Central de Asturias 
H. Central de Asturias 
H. Central de Asturias 
H. Central de Asturias 
H. Central de Asturias 
H. Central de Asturias 
H. Central de Asturias 
H. Central de Asturias 
H. Central de Asturias 
H. Central de Asturias 
H. Central de Asturias 


















Thrombophilia (Mut G1691A factor V) (Mut 
G20210A protrombina) 
H. Central de Asturias. 127 
METABOLIC CONDITIONS 





Factor V deficiency 
Nefronoptisis(NPHPI) 
Polycystic Kidney Disease 1 
Polycystic Kidney Disease 2 
Protrombine gene 
SRY gene 
(FGFR3) H. Central de Asturias. 
H. Central de Asturias. 
H. Central de Asturias. 
H. Central de Asturias. 
H. Central de Asturias. 
H. Central de Asturias. 
H. Central de Asturias. 
H. Central de Asturias. 
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BALEARES 
Population: 878.627 inhabitants. 
There is only 1 centre, a public hospital, in which genetic tests are performed. 
The number of conditions that can be tested in that centre is 19. 
NEUROLOGIC CONDITIONS 




Mental retardation FRAXE type linked (FMR2) 
Miller-Dieker syndrome 
Prader Willi syndrome 
Silver-Russel syndrome 
Smith-Magenis syndrome 
Torsion dystonia (DYT1) 
Williams-Beuren syndrome (LOH , FISH) 
(ATP7B) 
Centres 
H. Son Dureta Mallorca 
H. Son Dureta Mallorca 
H. Son Dureta Mallorca 
H. Son Dureta Mallorca 
H. Son Dureta Mallorca 
H. Son Dureta Mallorca 
H. Son Dureta Mallorca 
H. Son Dureta Mallorca 
H. Son Dureta Mallorca 
H. Son Dureta Mallorca 















Chimerism determination for bone marrow 





Di George syndrome 
Hemochromatosis 
Polycystic Kidney Disease 1 
Polycystic Kidney Disease 2 
H. Son Dureta Mallorca 
H. Son Dureta Mallorca 
H. Son Dureta Mallorca 
H. Son Dureta Mallorca 
H. Son Dureta Mallorca 
H. Son Dureta Mallorca 
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CANARIAS 
Population: 1.781.366 inhabitants. 
There are 2 centres in which genetic tests are performed, both of them public hospitals. 
The number of conditions that can be tested in those centres is 21. 
NEUROLOGIC CONDITIONS 
Alzheimer disease(Presenilina 1, APP, APOE) 
Angelman syndrome 
Duchenne - Becker muscular dystrophy 
Fragile-X syndrome 
Mental retardation FRAXE type linked (FMR2) 
Myotonic dystrophy Steinert 
Prader Willi syndrome 
Williams-Beuren syndrome (LOH , FISH) (ATP7B) 
Centres 
H. Universitario Tenerife 
H.Universitario Las Palmas 
H.Universitario Las Palmas 
H.Universitario Las Palmas 
H.Universitario Las Palmas 
H.Universitario Las Palmas 
H.Universitario Las Palmas 
H.Universitario Las Palmas 













Thrombophilia (Mut G1691A factor V) (Mut G20210A 





H.Universitario Las Palmas 
H. Universitario Tenerife 








Deafness, linked to Conexina 26 gene 




H.Universitario Las Palmas 
H. Universitario Tenerife 
H.Universitario Las Palmas 
H. Universitario Tenerife 
H.Universitario Las Palmas 
H. Universitario Tenerife 
H. Universitario Tenerife 
H. Universitario Tenerife 
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CANTABRIA 
Population: 537.606 inhabitants. 
There is only 1 centre, a public hospital, in which genetic tests are performed. The 
number of conditions that can be tested in that centre is 21. 
NEUROLOGIC CONDITIONS 
Alzheimer disease(Presenilina 1, APP, APOE) 
Charcot-Marie-Tooth neuropathy 
Friedrich ataxia 
Myotonic dystrophy Steinert 
Neurophathy due to pressure sensitivity 
Schizophrenia 



















Thrombophilia (Mut. G1691A factor V) (Mut. 
G20210A protrombina) 
Thrombophilia (Mut G20210A, protrombina) 











Β. Cesar-Chediak-Higashi disease 
Complement deficiencies 
Di George syndrome 
HLA type II molecules deficiency 
Inmunologic poligenetic diseases screening 
LAD deficiencies type I and type II 
Omenn syndrome Mut gene RAG1 





















Adenomatous polyposis of the colon (APC) 
Gen APC 
Adenomatous polyposis ofthe colon (APC) 
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CASTILLA-LA MANCHA 
Population: 1.755.053 inhabitants. 
There is only 1 centre, a public hospital, in which genetic tests are performed. The 




Prader Willi syndrome 
Williams-Beuren syndrome (LOH , FISH) (ATP7B) 
Centres 
H. Virgen de la Salud Toledo 
H. Virgen de la Salud Toledo 
H. Virgen de la Salud Toledo 
H. Virgen de la Salud Toledo 






Leukemia and limphoma H. Virgen de la Salud Toledo 375 
OTHER CONDITIONS 
Azoospermia H. Virgen de la Salud Toledo 86 
CASTILLA - LEON 
Population: 2.479.425 inhabitants. 
There are 2 centres in which genetic tests are performed, both of them are public 
university centres. The number of conditions that can be tested in those centres is 22. 
NEUROLOGIC CONDITIONS 
Alzheimer disease(Presenillna 1, APP 
Friedrich ataxia 
Fragile-X syndrome 
Kennedy disease. (AR, exón 1) 
Parkinson (Parkin, a-sinucleina) 
, APOE) 




Instituto Biología Genética 
Molecular. Valladolid 
Instituto Biología Genética 
Molecular. Valladolid 
Instituto Biología Genética 
Molecular. Valladolid 
U. Salamanca 











Breast cancer (BCRA1 y BCRA2) 
CK-19 
GST mu (colon, vejiga) 
K-RAS (CODON 12, 13) (lung, colon, 
Li-Fraumeni disease (p53) 
p53 EXONES 4,5,6,7,8 (Lung, breast, 
endometrio) 



























Wilson disease (ATP7B) 
U. Salamanca 
Instituto Biología Genética 
Molecular. Valladolid 
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CATALUNA 
Population: 6.361.365 inhabitants. 
There are 9 centres in which genetic tests are performed, of them 5 are public hospitals 
centres and 4 private centres. 
The number of conditions that can be tested in those centres is 70. 
NEUROLOGIC CONDITIONS Centres N.test 2001 
Alzheimer disease(Presenilina 1, APP, APOE) Hospital Clínico Barcelona 




Aneuploidies due toQF-PCR Laboratorio de Análisis Dr. Echevarne Barcelona 460 
Angelman syndrome Hospital Sant Joan de Déu, Barcelona 44 
H. Parc Tauli Barcelona 23 
H. del Mar - UPF Barcelona 2 
Laboratorio de Análisis Dr. „ 
Echevarne Barcelona 
Charcot-Marie-Tooth neuropathy IRO Barcelona 
Hospital Sant Joan de Déu, Barcelona 





Dentatorubral-pallidoluysian atrophy (DRPLA) 
(Dentatorubropalidoluisiana) IRO Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
Dominant ataxias (ADCAS) SCA1; SCA2 
(Machado) SCA3; SCA6; SCA7; SCA8; SCA9; 
SCA10; SCA12 
IRO Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
Friedrich ataxia Hospital Sant Joan de Déu, Barcelona 
IRO Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
Hospital Clínico Barcelona 
203 
64 
Duchenne - Becker muscular dystrophy 
Fragile-X syndrome 
H. San Pablo Barcelona 
Hospital Sant Joan de Déu, Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
Hospital Sant Joan de Déu, Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 














Kennedy disease. (AR, exón 1) 
Leber optic atrophy 
Mental retardation FRAXE type 
MELAS 
MELAS y MERRF 
MERRF 
Myotonic distrophy of waists (LGMD) 
Myotonic dystrophy Steinert 
Hospital Clínico Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
Hospital Clínico Barcelona 
H. San Pablo Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
IRO Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
Hospital Clínico Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
IRO Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
H. San Pablo Barcelona 
H. San Pablo Barcelona 
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NARP 
Neurofibromatosis type 1 
Neurofibromatosis type 2 
Neurophathy due to pressure sensitivity 
Parkinson (Parkin, a-sinucleina) 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
IRO Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
Hospital Sant Joan de Déu, Barcelona 
IRO Barcelona 
Hospital Sant Joan de Déu, Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 










Prader Willi syndrome Hospital Sant Joan de Déu, Barcelona 
H. Pare Tauli Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 







Spinal muscular atrophy (Werdnig-Hoffmann y 
Kugelberg-Welander) (SMN) 
Williams-Beuren syndrome (LOH , FISH) (ATP7B) 
Wolfram syndrome 
Hospital Sant Joan de Déu, Barcelona 
H. del M a r - UPF Barcelona 
H. San Pablo Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
H. del Mar -UPF Barcelona 
H. Pare Tauli Barcelona 

















Thrombophilia (Mut G1691A factor V) (Mut 
G20210A protrombina) 
NEOPLASIC CONDITIONS 
Adenomatous polyposis ofthe colon (APC) 
Breast cancer (BCRA1 y BCRA2) 
Familiar medullar thyroid cancer FMTC 
Li-Fraumeni disease (p53) 
Multiple Endocrine Neoplasia type 1 (MEN1) 
Non polyposic colonic cancer 
p53 EXONES 4,5,6,7,8 (Lung, breast, ovary, 
endometrio) 
Von Hippel-Lindau 
H. San Pablo Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
H. San Pablo Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
H. San Pablo Barcelona 
H. San Pablo Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
H. San Pablo Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
H. del Mar - UPF Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
IRO Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
H. San Pablo Barcelona 
H. del Mar - UPF Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
Hospital Clínico Barcelona 
H. San Pablo Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
Hospital Clínico Barcelona 
Hospital Clínico Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 


























5 a-reductasa deficiency type 2 Gene SRD5A2 H. Valle Hebrón Barcelona 5 
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Maturity-onset diabetes of the young MODY type 
(GK, HNF1) 
GH deficiency. Gene GH1 
Hunter disease 
Hurler disease 
Smitz-Lemli-Opitz syndrome 7- Esteral Reductase 
(DRCR7) 
H. Valle Hebrón 
Hospital Sant Joan de Déu, Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
Laboratorio de Analisis Dr. 
Echevarne Barcelona 
Hospital Clinico Barcelona 
Hospital Clinico Barcelona 
H. Valle Hebrón Barcelona 
Hospital Clinico Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
Hospital Clinico Barcelona 













Androgenic resistances: Morris syndrome, 




H. Valle Hebrón Barcelona 
Hospital Clinico Barcelona 
Hospital Clinico Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
Centro de Patología Celular. Barcelona 
IRO Barcelona 









Cystic fibrosis IRO Barcelona 574 
Centro de Patologia Celular. Barcelona 44 
Hospital Sant Joan de Déu, Barcelona 31 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 13 
Hospital Clinico Barcelona N/S 
Di George syndrome 
Di George syndrome/ S. Velocardiofacial (FISH) 







Norrie disease (NDP) 
Rickets D-vit resistant VDR gene 
Retinitis pigmentosa, autosomal recesive 
Retinitis pigmentosa, X-linked 
Russel Silver syndrome, primordial dwarf (Disomia 
uniparental cr. 7, duplicación 7p) 
Sex determination 
SRY gene 
Wilson disease (ATP7B) 
Centra de Patología Celular. 
H. Parc Tauli Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
IRO Barcelona 
H. San Pablo Barcelona 
H. San Pablo Barcelona 
Hospital Clínico Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
IRO Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
Hospital Sant Joan de Déu, ! 




Hospital Valle Hebron. Barcelona 
Hospital Clínico Barcelona 
IRO Barcelona 
Laboratorio de Análisis Dr. 
Echevarne Barcelona 
H. Valle Hebrón Barcelona 
H. San Pablo Barcelona 
H. San Pablo Barcelona 
H. del Mar - UPF Barcelona 
Hospital Sant Joan de Déu, 
Centro de Patología Celular. 
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COMUNIDAD VALENCIANA 
Population: 4.202.608 inhabitants. 
There are 5 centres in which genetic tests are performed, of them 3 are public centres 
(1 hospital and 2 university centres) and 2 private. 
The number of conditions that can be tested in those centres is 57 
NEUROLOGIC CONDITIONS 
Alzheimer disease(Presenilina 1, APP, APOE) 
Angelman syndrome 
Charcot-Marie-Tooth neuropathy 





H. La Fe. Valencia 
IGEM Valencia 
H. La Fe. Valencia 
IGEM Valencia 
H. La Fe. Valencia 
H. La Fe. Valencia 
IGEM Valencia 









Dominant ataxias (ADCAS) SCA1 ; SCA2 (E. de 
Machado) SCA3; SCA6; SCA7; SCA8; SCA9 
SCA10;SCA12 








Kennedy disease. (AR, exón 1) 
Mental retardation FRAXE type linked (FMR2) 
Myotonie dystrophy Steinert 
Neurophathy due to pressure sensitivity 
Prader Willi syndrome 
Spinal muscular atrophy (Werdnig-Hoffmann y 
Kugelberg-Welander) (SMN) 
Torsion dystonia (DYT1) 
Williams-Beuren syndrome (LOH , FISH) (ATP7B) 
H. La Fe. Valencia 
IGEM Valencia 
H. La Fe. Valencia 
IGEM Valencia 
ANCOR Alicante 
H. La Fe. Valencia 
IGEM Valencia 
H. La Fe. Valencia 
IGEM Valencia 
H. La Fe. Valencia 
H. La Fe. Valencia 
H. La Fe. Valencia 
IGEM Valencia 
H. La Fe. Valencia 
IGEM Valencia 
H. La Fe. Valencia 
IGEM Valencia 
H. La Fe. Valencia 
IGEM Valencia 
H. La Fe. Valencia 
IGEM Valencia 




























Inmunodeficiencia type Bruton 
Leukemias 
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METABOLIC CONDITIONS 
Hunter disease H. La Fe. Valencia 2 
NEOPLASIC CONDITIONS 
Adenomatous polyposis of the colon (APC) 
Breast cancer (BCRA1 y BCRA2) 
Li-Fraumeni disease (p53) 
Familiar feochromocitome 
Instability in microsatelites MSI Panel 5 Markers 
K-RAS (CODON 12, 13)(lung, colon, ovary, larynx) 
Multiple Endocrine Neoplasia MEN2A 
Multiple Endocrine Neoplasia MEN2B 
p53 EXONES 4,5,6,7,8 (Lung, breast, ovary, 
endometrio) Sarcomas 
Retinoblastoma 
Sporadic Cancer: kidney 
Sporadic Cancer : bladder 
Sporadic Cancer: Meningiomas 
Sporadic Cancer: Neuroblastomas 
Sporadic Cancer: Sarcomas 
Von Hippel Lindau disease 
H. La Fe. Valencia 
ANCOR Alicante 
ANCOR Alicante 
H. La Fe. Valencia 
ANCOR Alicante 
ANCOR Alicante 
H. La Fe. Valencia 
H. La Fe. Valencia 
U. Valencia 
ANCOR Alicante 




























Di George syndrome 
Emery-Dreifuss disease 
Epidermolisis bullosa distrofica 
Factor V deficiency 
Hemochromatosis 
Hipercolesterolemia Familiar y gen SRY 
Incontinentia pigmenti 
Mental retardation familiar 
Miller-Diecker syndrome 
Retinosquisis 
Uniparental Disomy 14 
Usher syndrome 
WAGR syndrome 
H. La Fe. Valencia 
IGEM Valencia 
H. La Fe. Valencia 
IGEM Valencia 
H. La Fe. Valencia 
IGEM Valencia 
H. La Fe. Valencia 
H. La Fe. Valencia 
ANCOR Alicante 





H. La Fe. Valencia 
H. La Fe. Valencia 
H. La Fe. Valencia 
H. La Fe. Valencia 
H. La Fe. Valencia 
H. La Fe. Valencia 























Population: 1.073.381 inhabitants. 
There is 1 centre, a public hospital, in which genetic tests are performed. 




Prader Willi syndrome 
Smith-Magenis syndrome 
Williams-Beuren syndrome (LOH FISH) (ATP7B) 
Centres 
H. Materno Infantil Badajoz 
H. Materno Infantil Badajoz 
H. Materno Infantil Badajoz 
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GALICIA 
Population: 2.732.926 inhabitants. 
There are 4 centres in which genetic tests are performed, 3 of them are public hospitals 
and 1 private. 
The number of conditions that can be tested in those centres is 69. 
NEUROLOGIC CONDITIONS 
Alzheimer disease(Presenilina 1, APP, APOE) 
Angelman syndrome 
Charcot-Marie-Tooth neuropathy 
Dentatorubral-pallidoluysian atrophy (DRPLA) 
(Dentatorubropalidoluisiana) 
Dominant ataxias (ADCAS) SCA1; SCA2 (Machado) 
SCA3; SCA6; SCA7; SCA8; SCA9; SCA10; SCA12 




Leber optic atrophy 
Mental retardation FRAXE type linked (FMR2) 
Myotonic dystrophySteinert 
Neurophathy due to pressure sensitivity 
Prader Willi syndrome 
Rett syndrome 
Smith-Magenis syndrome 
Williams-Beuren syndrome (LOH , FISH) (ATP7B) 
Centres 
H. Conxo. Santiago 
Centro Oncológico de Galicia 
Hospital Clínico Santiago 
H. Conxo. Santiago 
Hospital Clínico Santiago 
H. Conxo. Santiago 
Hospital Clínico Santiago 
Centro Oncológico de Galicia 
Hospital Clínico Santiago 
Centro Oncológico de Galicia 
Hospital Clínico Santiago 
Hospital Clínico Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
Hospital Clínico Santiago 
H. Conxo. Santiago 
Hospital Clínico Santiago 
Hospital Clínico Santiago 
H. Conxo. Santiago 
Centro Oncológico de Galicia 
Hospital Clínico Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
Hospital Clínico Santiago 
H. Conxo. Santiago 






























Chimerism for bone marrow transplants 
Leukemias 
Leukemias y linfomas (traslocaciones) 
Mut C>T 677 gene MTHFR 
Thrombophilia (Mut G1691A factor V) (Mut G20210A 
protrombina) 
von Willebrand disease 
Centro Oncológico de Galicia 
H. Conxo. Santiago 
Centro Oncológico de Galicia 
H. Conxo. Santiago 
Hospital Juan Canalejo 
H. Conxo. Santiago 









Adenomatous polyposis ofthe colon (APC) 
Breast cancer (BCRA1 y BCRA2) 
Li-Fraumeni disease (p53) 
Multiple Endocrine Neoplasia MEN2A 
Multiple Endocrine Neoplasia MEN2B 
p53 EXONES 4,5,6,7,8 (Lung, breast, ovary, 
endometrio) 
Tirosinasa (eel. Circulantes, cáncer de tiroides) 
Tirosinasa (cel. Circulantes, melanoma) 
Von Hippel Lindau disease 
H. Conxo. Santiago 
H. Conxo. Santiago 
Centro Oncológico de Galicia 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
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Adrenal hyperplasia, congenital 
Alpha-1-antitripsina deficiency 
Apolipoprotein Β (APOB) deficiency 
Cerebrotendinosis xantomatosa (CYP27) 
Growth Hormone deficiency 
Hypercholesterolemia 
Insensibility to GH syndrome 
Lipodistrofia Parcial Familiar 
Primary hyperaldosteronism 
Triple A syndrome 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 


















Androgenic Resistances: Morris syndrome, 




Di George syndrome 
Factor V deficiency 
Hemochromatosis 
Hipoplasia adrenal congénita 
Holoprosencefalia 
Homocistinuria 




Poliendrocrinopathy autoinmune type 1 
Polycystic Kidney Disease 1 
Polycystic Kidney Disease 2 
Pseudohipoparatiroidismo 
SRY gene 
Wilson disease (ATP7B) 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
Centro Oncológico de Galicia 
Centro Oncológico de Galicia 
Hospital Clínico Santiago 
Centro Oncológico de Galicia 
H. Conxo. Santiago 
Hospital Clínico Santiago 
Centro Oncológico de Galicia 
H. Conxo. Santiago 
Hospital Clínico Santiago 
H. Conxo. Santiago 
Centro Oncológico de Galicia 
H. Conxo. Santiago 
Hospital Clínico Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
Hospital Clínico Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
H. Conxo. Santiago 
Centro Oncológico de Galicia 
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MADRID 
Population: 5.372.433 inhabitants. 
There are 9 centres in which genetic tests are performed, of them 8 are public centres 
(6 hospitals and 1 university centres and 2 research centres) and 1 private hospital. 




Criptic chomosomic alterations (FISH, Multitest-Ty C) 
Dentatorubral-pallidoluysian atrophy (DRPLA) 
Distrofias maculares dominantes (gen RDS/periferina) 
Dominant ataxias (ADCAS) SCA1; SCA2.(Machado) 
SCA3; SCA6; SCA7; SCA8; SCA9, SCA10; SCA12 




Kallman (microdel Xp22) 
Myotonic dystrophySteinert 
Mental retardation FRAXE type linked (FMR2) 
Neurofibromatosis 
Neurophathy due to pressure sensitivity 
Norrie disease 
Prader Willi syndrome 
Smith-Magenis syndrome 
Spinal muscular atrophy (Werdnig-Hoffmann y 
Kugelberg-Welander) (SMN) 
Torsion dystonia (DYT1 ) 
Williams-Beuren syndrome (LOH , FISH) (ATP7B) 
Centres 
F. Jiménez Díaz 
F. Jiménez Díaz 
Centro Investigación Anomalías 
Congénitas Madrid. 
F. Jiménez Díaz 
F. Jiménez Díaz 
F. Jiménez Díaz 
F. Jiménez Díaz 
H. La Paz. Madrid 
H. Ramón y Cajal 
F. Jiménez Díaz 
F. Jiménez Díaz 
F. Jiménez Díaz 
F. Jiménez Díaz 
H. La Paz. Madrid 
F. Jiménez Díaz 
F. Jiménez Díaz 
H. Ramón y Cajal 
F. Jiménez Díaz 
F. Jiménez Díaz 
F. Jiménez Díaz 
F. Jiménez Díaz 
H. Ramón y Cajal 
F. Jiménez Díaz 




























Thrombophilia (Mut G1691A factor V) (Mut G20210A 
protrombina) 
F. Jiménez Díaz 




Adenomatous polyposis ofthe colon (APC) 
Breast cancer (BCRA1 y BCRA2) 
Familiar feochromocitome 




Multiple Endocrine Neoplasia MEN2A 
Non poliposic Colonic Cancer 
Other oncohematologic conditions 
p53 EXONES 4,5,6,7,8 (Lung, breast, ovary, 
endometrio) 
PTEN 
Von Hippel Lindau disease 
CNIO Madrid 
H. San Carlos Madrid 
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Adrenal hyperplasia, congenital 
Alpha-1-antitripsina deficiency 
Carnitine palmitoil transferasa II deficiency, 
fenotype muscular, mutacións S113L 
H. Gregorio Marañón 
H. Gregorio Marañón Madrid 
H. La Paz. Madrid 
H. La Paz. Madrid 
H. Gregorio Marañón 
H. La Paz. Madrid 








Carnitina Palmitoil Transferasa II deficiency 
(Mutación Y628S) 
H. 12 de Octubre 





Diabetes type MODY. (GK, HNF1) 
Fenilcetonuria-Fenialaninemia (PAH) 
GH deficiency 
HLA of susceptibility to diabetes type I 
Insensibility to GH 
McArdle disease (défict de miofosforilasa). 
Mutaciones R49X, G204S y W797R 
Metil crotonil glicinuria (Genes MCCA y MCCB) 
MCAD Medium Chain Acil-CoA deshidrogenasa 
deficiency (Mutation K304E) 
Mioadenilato desaminasa deficiency, mutación 
Q12X 
Propionic acidemia 
Propionic acidemia (Genes PCCA and PCCB) 
H. La Paz. Madrid 
Centro de Diagnóstico de 
Enfermedades Moleculares 
Madrid 
H. La Paz. Madrid 
H. La Paz. Madrid 
H. La Paz. Madrid 
H. 12 de Octubre 
Centro de Diagnóstico de 
Enfermedades Moleculares 
Madrid 
Centro de Diagnóstico de 
Enfermedades Moleculares 
Madrid 
H. 12 de Octubre 
Centro de Diagnóstico de 
Enfermedades Moleculares 
Madrid 















Agammaglobulinemia autosomic (μ chain) 
Agammaglobulinemia X-linked 
Apoptosis deficiency ( APO 1) 
Combined Inmunodeficiency X- linked ( cad yR-
IL2) 
Hyper IgM syndrome 
RAG 1, RAG 2. Combined autosomic 
Inmunodeficiency 
H. La Paz. Madrid 
H. La Paz. Madrid 
H. La Paz. Madrid 
H. La Paz. Madrid 
H. La Paz. Madrid 















Deafness, linked to Conexina 26 gene 
H. Gregorio Marañón Madrid 
H. La Paz. Madrid 
F. Jiménez Díaz 
F. Jiménez Díaz 
F. Jiménez Díaz 
H. La Paz. Madrid 
H. Ramón y Cajal 
F. Jiménez Díaz 
H. Gregorio Marañón Madrid 
H. Ramón y Cajal 
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Deafness, mitochondrial 
Deafness, mitochondrial, mutación A1555G 
Deafness mitochondrial (due to ototoxics) 
Deafness, sporadic (otoferlina gene) 
Di George syndrome 
Factor V deficiency 
GH deficiency 
Hemochromatosis 
Mediterranean familiar fever 
Polimorfisms Metabolism Folato: MTHFR 
677C—Τ 
Polimorfisms Metabolism Folato: MTRR 66 G—>A 
Polycystic Kidney Disease I (PKD1) 
Porphyria Acute Intermitent (AIP) 
Porphyria, congenital erythropoietic 
Protrombine gene 
Retinitis pigmentosa 
Retinitis pigmentosa, autosomic dominant (genes 
RHOyRDS) 
Retinitis pigmentosa X-linked 
Retinoschisis 
SOS gene linked conditions 
SRY gene 
Wilson disease (ATP7B) 
H. Ramón y Cajal 
H. 12 de Octubre 
H. Ramón y Cajal 
F. Jiménez Díaz 
F. Jiménez Díaz 
H. Gregorio Marañón Madrid 
H. La Paz. Madrid 
F. Jiménez Díaz 
H. La Paz. Madrid 
F. Jiménez Díaz 
F. Jiménez Díaz 
Centro de Diagnóstico de 
Enfermedades Moleculares 
Madrid 
Centro de Diagnóstico de 
Enfermedades Moleculares 
Madrid 
H. Ramón y Cajal 
H. La Paz. Madrid 
H. La Paz. Madrid 
F. Jiménez Díaz 
H. Gregorio Marañón Madrid 
F. Jiménez Díaz 
F. Jiménez Díaz 
F. Jiménez Díaz 
F. Jiménez Díaz 
H. La Paz. Madrid 
H. La Paz. Madrid 
F. Jiménez Díaz 
H. Gregorio Marañón Madrid 






























Population: 1.190.378 inhabitants. 
There is only 1 centre, a public hospital, in which genetic tests are performed. The 




Duchenne - Becker muscular dystrophy 
Fragile-X syndrome 
Myotonic dystrophy Steinert 
Prader Willi syndrome 
Centres 
Centro de Bioquímica y Genética Clínica 
Centro de Bioquímica y Genética Clínica 
Centro de Bioquímica y Genética Clínica 
Centro de Bioquímica y Genética Clínica 
Centro de Bioquímica y Genética Clínica 











Multiple Endocrine Neoplasia MEN2A 
Lynch syndrome (HNPCC) 
Centro de Bioquímica y Genética Clínica 
Centro de Bioquímica y Genética Clínica 








Centro de Bioquímica y Genética Clínica 
Centro de Bioquímica y Genética Clínica 
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NAVARRA 
Population: 556.263 inhabitants. 
There are 2 centres, 1 public hospital and 1 private hospital, in which genetic tests are 
performed. 
The number of conditions that can be tested in those centres is 44. 
NEUROLOGIC CONDITIONS 
Alzheimer disease(Presenilina 1, APP, APOE) 
Angelman syndrome 
Charcot-Marie-Tooth neuropathy 
Dentatorubral-pallidoluysian atrophy (DRPLA) 
Dominant ataxias (ADCAS) SCA1; 






Kennedy disease (AR, ΘΧΟΠ 1 ) 
Leber optic atrophy 
Mental retardation FRAXE type linked (FMR2) 
Myotonic dystrophy Steinert 
Parkinson (Parkin, a-sinucleina) 
Prader Willi syndrome 
Torsion dystonia (DYT1 ) 
X-Frágile syndrome (FMR1) 
Centres 
H Virgen del Camino 
Clínica Universitaria Pamplona 
H Virgen del Camino 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
H Virgen del Camino 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
H Virgen del Camino 
H Virgen del Camino 
Clínica Universitaria Pamplona 
H Virgen del Camino 
Clínica Universitaria Pamplona 























Metilen TetraHidrofolato Reductase (MTHFR) 
Thrombophilia (Mut G1691A factor V) (Mut 
G20210A protrombina) 
H Virgen del Camino 
H Virgen del Camino 





Adenomatous polyposis of the colon (APC) 
Adenomatous polyposis ofthe colon (Gen P53, 
Gen kRAS, Gen hMHS2, Gen hMLH1, Gen 
hPMS1,GenhPMS2) 
Breast cancer (BCRA1 y BCRA2) 
CK-19 
Familiar feochromocitome 
Familiar melanoma (pl5, p19,CDK4) 
Familiar melanoma (pl6) 
GST mu (colon, bladder) 
K-RAS (CODON 12, 13) (lung, colon, ovary, 
larynx) 
Li-Fraumeni disease (p53) 
Multiple Endocrine Neoplasia type 1 (MEN1) 
Multiple Endocrine Neoplasia type II A (MEN2A) 
p53 EXONES 4,5,6,7,8 (Lung, breast, ovary, 
Endomet.) 
Von Hippel Lindau disease 
PSA (prostate cancer) 
Clínica Universitaria Pamplona 
H Virgen del Camino 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 
Clínica Universitaria Pamplona 




















H Virgen del Camino 
H Virgen del Camino 
5-10 
250 
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Cystic fibrosis 
Deafness, linked to Conexina 26 gene 
Di George syndrome 
Hemochromatosis 
Morris Syndrome, de Reifenstein Syndrome (AR 
exones 2-8) 
SRY gene 
Wilson disease (ATP7B) 
H Virgen del Camino 
Clinica Universitaria Pamplona 
H Virgen del Camino 
H Virgen del Camino 
Clínica Universitaria Pamplona 
H Virgen del Camino 









Population: 2.101.478 inhabitants in the year 2001. 
There are 4 centres in which genetic tests are performed, of them 3 are public hospitals 
and and 1 private. 





Mental retardation FRAXE type linked (FMR2) 
Myotonic dystrophy Steinert 
Myotonic distrophy of waists (LGMD) type 2A 
(Calpainopatia,LGMD2A) 
Parkinson (Parkin, a-sinucleina) 
Centres 
H. Donostia. San Sebastián 
H. Basurto Bilbao 
H. Cruces Baracaldo 
H. Basurto Bilbao 
H. Donostia. San Sebastián 
H. Cruces Baracaldo 
H. Basurto Bilbao 
H. Donostia. San Sebastián 















Diabetes type MODY. (GK, HNF1) 
H. de Cruces Baracaldo 





K-RAS (CODON 12, 13)(lung, colon, ovary, 
larynx) 
MEN1 
Multiple Endocrine Neoplasia MEN2A 
Multiple Endocrine Neoplasia MEN2B 
p53 EXONES 4,5,6,7,8 (Lung, breast, ovary, 
endometrio) 
Thyroid cancer 
H. Cruces Baracaldo 
H. Cruces Baracaldo 
H. Cruces Baracaldo 
H. Cruces Baracaldo 
H. Cruces Baracaldo 
H. Cruces Baracaldo 









Androgenic Resistances: Morris syndrome, 
Reifenstein syndrome (AR exones 2-8) 
Celiac disease (HLA markers) 
Cystic fibrosis 
Espondiloartropathy (genotyping b27) 
Factor V deficiency 
Hemochromatosis 
Hemochromatosis(Mutations C282Y, H63D, 
S65C) 




Reumathoid Artritis (hla markers) 
SRY gene 
H. Cruces Baracaldo 
Policlínica Gipuzkoa. San Sebastián 
H. Cruces Baracaldo 
Policlínica Gipuzkoa. San Sebastián 
H. Cruces Baracaldo 
H. Cruces Baracaldo 
Policlínica Gipuzkoa. San Sebastián 
Policlínica Gipuzkoa. San Sebastián 
H. Cruces Baracaldo 
H. Cruces Baracaldo 
H. Cruces Baracaldo 
Policlínica Gipuzkoa. San Sebastián 
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RIOJA 
Population: 270.400 inhabitants. 
There is only a public hospital in which genetic tests are performed. 









H. San Millán. Logroño 
H. San Millán. Logroño 
H. San Millán. Logroño 
H. San Millán. Logroño 
H. San Millán. Logroño 













H. San Millán. Logroño 
H. San Millán. Logroño 
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